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Abstract
Monogenic disorders, inherited conditions arising from single gene defects, include
more than 8,000 different entities with a worldwide prevalence of 10/1000 individuals.
Disease causing missense variants are very common in monogenic disorders and may
lead to various consequences at the protein and cellular levels. Therefore, a monogenic
disease may show variable onset, symptoms, and severity based on the type and
position of the mutation. Lysosomal storage disorders (LSDs) are a group of more than
60 monogenic metabolic disorders that are usually caused by deficiencies in specific
lysosomal enzymes due to genetic defects in their coding genes. Of all reported LSDs’
disease-causing mutations, the missense type is the most common covering more than
two thirds of the identified variants. In this thesis, two clinical cases of two LSDs
associated with different missense variants are presented. GM1-gangliosidosis is a
severe neurodegenerative LSD caused by genetic defects in the GLB1 gene encoding
β-Galactosidase (β-Gal) enzyme resulting in loss of residual enzymatic activity and
the subsequent accumulation of its corresponding substrates in affected cells and
tissues. Out of 152 GM1-gangliosidosis causing variants, more than 151 are from the
missense type. An Emirati child was admitted to the genetics clinic presented with an
infantile form of GM1-gangliosidosis where whole genome sequencing analysis
revealed the presence of a previously reported c.451G>T (p.D151Y) missense variant
in the GLB1. The loss of function effect of the underlying variant was a result of β-Gal
quantitative loss in lysosomes of patient’s fibroblast cells due to its retention in the
Endoplasmic Reticulum (ER). Partial correction of the trafficking defect of p.D151Y
β-Gal by glycerol and reduced temperature was an indication of the mutated enzyme
capacity to be rescued making it a potential candidate for enzyme enhancement therapy
using

pharmaceutical

chaperones

(PC).

Indeed,

the

butyl

derivative

of

Deoxygalactonojirimycin (DGJ) was able to partially promote the mutated β-Gal
processing to lysosomes and significantly enhance its residual activity in patient’s
cells. On the other hand, Schindler disease is an autosomal recessive LSD caused by
deficient alpha-N-acetylgalactosaminidase (α-NAGA) residual enzymatic activity.
Out of twelve reported cases worldwide, six of which are carriers of missense variants
with extreme variations in the clinical phenotype. A five-year-old Emirati child
presented with severe neurological manifestations was confirmed to be a Schindler
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disease case based on the marked loss of enzymatic activity. Although his sister
showed similar degree of enzymatic loss, she did not present clinical symptoms.
Different molecular analyses revealed that the underlying amino acid substitution did
not interfere with the enzyme processing and trafficking to lysosomes but negatively
affected the enzyme active site pocket structural configurations that restricted its
substrate binding. Overall, understanding the nature and the consequences of the
causative genetic defects will improve the genotype/phenotype correlations and open
new opportunities for therapeutic interventions.
Keywords: Lysosomal storage disorders, Missense variants, GM1 gangliosidosis,
Schindler disease, Misfolded proteins, Pharmaceutical chaperones.
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)Title and Abstract (in Arabic

توضيح تأثير بدائل األحماض األمينية في اضطرابات التخزين الجسدي :دروس وأفكار
من ( )GM1-gangliosidosisو ()Schindler disease
الملخص

تشمل االضطرابات وحيدة الجين ،وهي حاالت موروثة ناشئة عن عيوب جينية وحيدة ،أكثر من
 10000نوع مختلف من الحاالت التي ينتشر فيها على نطاق العالم بنسبة  1000/10فرد.
الطفرات الجينية من نوع ال ( )Missense mutationsشائعة جدا في االضطرابات وحيدة الجين
التي قد تؤدي إلى عواقب مختلفة على مستوى البروتين .لذلك ،قد يبدي مرض معين أعراض
وشدة مختلفة تختلف من مريض آلخر استنادًا إلى نوع وموقع الطفرة .اضطرابات تخزين
الاليزوسومية هي مجموعة من أكثر من  60اضطراب أيضي والتي عادة ما تكون ناتجة عن
عيوب في إنزيمات اليزوسومية محددة وذلك بسبب عيوب جينية في جينات الترميز الخاصة بها.
ومن بين كل الطفرات المسببة لهذه األمراض والتي تم تسجيلها ،فإن الطفرات ال ()missense
هي األكثر شيوعا ً والتي تمثل أكثر من ثلثي المتغيرات المكتشفة .في هذه الدراسة ،سيتم عرض
حالتين سريريتين لنوعين من امراض اضطرابات تخزين الاليزوسومية مرتبطين بطفرات
( )missenseمختلفة )GM1-gangliosidosis( .مرض هو اضطراب عصبي شديد ناجمة عن
عيوب وراثية في جين ( )GLB1المسؤول عن انتاج انزيم ( )beta galactosidaseينتج عنه فقدان
النشاط اإلنزيمي وتراكم الالحق للركائز المقابلة له في الخاليا واألنسجة المتأثرة .من أصل 153
طفرة متعلقة ب ( ،)Gm1-gangliosidosisأكثر من  115منها من نوع ( .)missenseتم عرض
طفل إماراتي في عيادة علم الوراثة الذي كان يعاني من اعراض مرض ال GM1-
 gangliosidosisحيث تم كشف تحليل تسلسل الجينوم الكامل عن وجود الطفرة
( )c.451G>T/p.D151Yفي جين  GLB1المسجلة سابقا كمسبب لهذا المرض .وكان فقدان التأثير
الوظيفي األساسي للطفرة المذكورة نتيجة للخسارة الكمية من االنزيم في الليزوسومات في الخاليا
الليفية للمريض نتيجة الحتجازه في منطقة ال  .ERكان تصحيح العيب الهيكلي األساسي في
االنزيم المعطوب عن طريق الجليسرول ودرجة الحرارة المنخفضة بمثابة مؤشر على قدرة
االنزيم على اإلنقاذ مما يجعله مرش ًحا محتمالً للعالج اإلنزيمي عن طريق أدوية ال
( .)Pharmaceutical chaperonesوقد تمكن مشتق البوتيل من ( )Deoxygalactonojirimycinمن
الترويج الجزئي للمعالجة لالنزيم المعطوب وتحفيز نقله إلى الليزوسومات وتعزيز نشاطه المتبقي

x

بشكل كبير في خاليا المريض .ومن ناحية أخرى ،فإن مرض ( )Schindlerهو مرض ايضي
نادر ناتج عم نقص النشاط اإلنزيمي ل ( )α-NAGAعلى نطاق واسع من الخاليا واألعضاء
المتأثرة بالمرض .من بين اثنا عشرة حالة تم التسجيل عنها في جميع أنحاء العالم ،ستة منها تحمل
أشكال الطفرات ال ( )missenseالتي تنجم عن اختالف شاسع في االعراض السريرية من مريض
ألخر .وقد تأكد أن طفل إماراتي يبلغ من العمر خمس سنوات ،قدم بمظاهر عصبية حادة ،هو
حالة مرض ( ،)Schindlerوذلك على بناء على النقص الملحوظ للنشاط اإلنزيمي (.)NAGA
كشفت تحليالت جزيئية مختلفة أن استبدال حمض األميني األساسي لألنزيم لم يؤثر على نقل
اإلنزيم الى الليزوسومات ولكنه أثر سلبا على التكوينات الهيكلية لجيب الموقع النشاط اإلنزيمي
التي قيدت ربطه بمركباته .وفي اإلجمال ،فإن فهم طبيعة وعواقب العيب الجيني المسبب للمرض
من شأنه أن يحسن من التفسيرات السريرية للمرضى ويساعد األطباء عل التكهن بالنهج الصحيح
في تدخالت العالجية تتناسب مع كل مريض على حدا.
مفاهيم البحث الرئيسية :اضطرابات التخزين الجسدي ،الطفرات الجينية ،النواقل الدوائية ،تشابك
بروتيني ،داء شندلر ،مرض .GM1-gangliosidosis
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Chapter 1: Introduction
1.1 Overview
Lysosomal storage diseases (LSDs) are a heterogenic subgroup of more than
60 rare inborn inherited metabolic disorders with the majority being inherited in an
autosomal recessive manner [1]. Individual LSDs are usually caused by deficiencies
in specific lysosomal enzymes due to genetic defects in their coding genes. Genetic
defects will either disrupt the expression of the mutated protein or result in the
expression of a structurally or functionally defective enzyme. In all cases, the residual
enzyme activity will be lower than the cellular threshold required to carry out the
normal biological function. The major outcome of low lysosomal enzyme activity is
the accumulation of its substrates in lysosomes leading to toxicity, cell swelling, and
cell death [2]. Disease symptoms are more linked to the type of the accumulated
substrate and the location of the affected tissue(s). However, LSDs pathological effects
on lysosomal enzyme processes and pathways are not fully clear yet. The genotypephenotype correlation of LSDs has been extensively studied to link symptoms to the
genetic defect, but little is known so far on understanding the cellular mechanisms by
which the mutations cause the underlying disorder. Missense mutations (substitution
of an amino acid by another in the protein sequence) are very frequent in LSDs, but
their pathogenic effects are the most difficult to establish, especially their underlying
cellular mechanisms. Missense variants’ effects depend mostly on the site of change
at the protein level. Amino acid substitution changes in the enzyme active site are
believed to be the most deleterious, leading to almost complete loss of residual enzyme
activity [3, 4]. Missense changes outside the active site may affect the folding
properties and trafficking of the mutated protein, hence, its possible retention in the
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endoplasmic reticulum (ER) by the ER quality control machinery. ER-retained
enzymes will either form aggregates and accumulate in the ER or will be recognized
and tagged by the ER-associated degradation machinery (ERAD) and directed for
proteasomal premature degradation [5, 6]. It has been observed that misfolded ERretained lysosomal enzymes may partially retain some of their enzymatic activities,
but the loss of function effect of such proteins is due to trafficking defects and
consequently the quantitative absence from lysosomes.
Treatments for LSDs are often directed toward relieving the disease symptoms
through supportive medical therapies. Understanding the pathophysiology behind
LSDs might have profound multiple therapeutic implications to increase the lost
residual enzyme activities in different LSDs. Clinical studies have shown that a 10%
enzymatic residual activity in most of LSDs is enough to enhance patients’ clinical
presentation and slow down disease progression [7]. Based on these findings, multiple
treatment approaches have been proposed. Enzyme replacement therapy (ERT) is
commonly used to treat patients with such disorders but the use of recombinant
enzyme infusions comes with many limitations [8]. The major limitation of ERT is the
huge size of the delivered recombinant enzymes which do not diffuse easily into all
affected tissues like bone, cartilage, and skeletal muscle. ERT also has a low capacity
to ameliorate neurological manifestations which are presented in two-third of LSD
patients because recombinant enzymes cannot cross the blood-brain barrier. Small
molecular weight compounds therapy has been proposed as an alternative to ERT in
multiple LSDs presented with missense mutations affecting protein structural
conformation and folding properties to overcome these limitations. Small molecular
weight compounds like pharmaceutical chaperones (PCs) and proteostasis regulators
(PRs) enhance lysosomal enzyme activity by specific binding to the mutated enzyme
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or manipulating different proteostasis pathways, respectively, promoting protein
stability and folding to enhance the enzymatic activity and trafficking of mutated
proteins [7]. Multiple compounds have been approved for clinical use to treat multiple
LSDs and some are still under research or in clinical trials.
1.2 Statement of the Problem
Missense variants in conformational diseases have various consequences on
the affected protein at the molecular level that is generally challenging to predict. In
lysosomal storage diseases, two-thirds of the reported disease-causing genetic defects
are of the missense type. The main focus in this study is, therefore, to delineate the
potential effects of missense variants in two clinical cases of lysosomal storage
diseases (infantile GM1-gangliosidosis and Schindler diseases) and to understand their
molecular pathogenesis at the cellular level using patients’ fibroblasts. In addition, we
aimed to analyze the potentiality of the amenable amino acid substitutions for rescue
from mislocalization and evaluate the potential use of pharmaceutical chaperones as a
mean of enzyme enhancement therapy.
1.3 Relevant Literature
1.3.1 Lysosomes: discovery, biogenesis and cellular functions
The digestive sac in the cell was identified by Christian de Duve biochemistry
research group in the early fifties [9]. Although the team main goal was to characterize
glucose 6-phosphatase enzyme in the liver, the experimental flow and the development
of centrifugal fractionation protocol led to the discovery of lysosomes [10]. In short,
glucose 6-phosphatase enzyme was precipitated with an unknown acidic cellular
structure while trying to study its relation to insulin in hepatic tissue. Then a decision
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has been made to focus the team’s efforts to find out more about this structure and
whether it has any relevance to the work which was conducted on insulin. Tissue
homogenates were applied to centrifugal fractionation and acid phosphatase activity
was analyzed in every fraction. Unexpectedly, the enzyme did not show the normal
activity levels and cellular fractions were stored under freezing temperature for future
analysis. Five days later, samples were reanalyzed for acid phosphatase activity which
surprisingly was elevated to normal levels. The possible explanation behind the
activity increase is that the enzyme was properly impacted within a membranous
cellular structure which was physically broken via the temperature change after
freezing the fractions freeing it to directly interact with the enzyme-substrate in the
reaction test tubes. Acid phosphate activity was found in both the mitochondrial and
microsomal fractions with various degrees. The fractionation protocol was adjusted in
a way to initiate the separation of an extra fraction with sedimentation properties
bringing it between the mitochondrial and microsomal fractions where acid
phosphatase activity was highest [10]. Further analysis of the new fraction identified
another five additional enzymes four of which resembled acid phosphatase acidic
hydrolase function for different substrates. Prior to that and with the collaboration with
Alex Novikoff’s team, lysosomes morphology was documented by electron
microscopy using acid phosphatase staining procedure as a marker for these
specialized organelles [11]. Afterward, lysosomes were extensively studied in
different tissue types and their function in digesting intracellular and extracellular
materials brought up the terms; endocytosis, autophagy, and exocytosis [12].
Lysosomes were also linked to different pathological disorders and the first book was
published in 1969 [13]. As its name indicates, lysosomes are mainly involved in
digesting and recycling different cellular metabolites and substrates. It handles both
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extracellular and intracellular molecules to generate energy and various building
blocks as per the cell’s need.
Consequently, it has been established that a lysosome is an enclosed
compartment with a lipid bilayer membrane that has a size ranging from 0.1 to 0.5 µm.
It holds more than 60 different types of acid hydrolases that aid the digestion
mechanism in the cell [14]. Lysosomes maintain an acidic environment of less than
5.0 pH that is required for the resident enzymes function and activity [15]. The acidic
pH is mostly maintained via actively pumping H+ ions into the lysosome through
specialized membrane-bound V-type proton pumps [16]. Unlike other organelles that
usually have a uniform structure, lysosomes are heterogeneous in size and shape. This
is most properly reflecting the various amounts and types of lysosomal content to be
digested [17]. Despite the mentioned heterogeneity, lysosomes can be identified by
specific histochemical markers like acid phosphatase [16]. Lysosomes formation
occurs via the intersection between the secretory pathway and endocytosis [18].
Extracellular macromolecules are taken up by the cell through endocytosis via
clathrin-coated vesicles from the cell membrane. Then, the endocytic vesicle gets
fused with early endosomes that eventually will mature into late endosomes where
some proteins will be recycled back to the plasma membrane [17]. Late endosomes
afterward will merge with the transporting vesicle budded from the trans-Golgi
apparatus carrying the specialized hydrolysis enzymes on mannose-6-phosphate
receptors (M6P) [16]. The former fusion results in the formation of lysosomes (Figure
1) [17]. Throughout the maturation and lysosomal formation process, the pH gradually
decreases to the optimum acidic degree for the hydrolases function.
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Figure 1: Lysosome biogenesis and formation
Schematic drawing of lysosomal formation via endocytosis where endocytic vesicles loaded with
extracellular material fuses with early endosomes that matures with late endosomes. The fusion of the
enclosed vesicle budded from the Golgi apparatus, carrying different acidic hydrolytic enzymes, with
late endosomes will mature into lysosomes. M6P receptors which were responsible for the delivery of
lysosomal enzymes to lysosomes will be recycled back to Golgi. Adapted from Cooper GM [17].
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In addition to molecules derived from the extracellular surroundings,
lysosomes also digest materials that are taken up via phagocytosis and autophagy [17].
Phagocytosis is a receptor-targeted ingestion of different materials like pathogens and
remnants of apoptotic cells [19]. This process is performed by a group of specialized
cells called phagocytes. Phagocytosis is initiated via a recognition step of particles
larger than 0.5 μm followed by its internalization through the plasma membrane
forming vesicles named as a phagosome. Phagolysosomes are then formed upon the
fusion of phagosomes with lysosomes that initiates the digestion process. Autophagy,
on the other hand, is a cellular recycling mechanism whereby the cell degrades its own
components and organelles by their enclosure in ER vesicles that fuse with lysosomes
generating autophagosome [20]. Autophagy is a physiological mechanism by which it
maintains normal haemostasis in the cell by getting rid of long-lived proteins and aged
organelles and recycling their building blocks.
The lysosome is an extremely dynamic organelle that is not only responsible
for metabolites and macromolecules digestion but it is also integrated into several
mechanisms and pathways to regulate normal cellular haemostasis and function [21].
First of all, lysosomes take place in the trafficking and export of the digested material
via three distinct pathways [15]. Degraded molecules in lysosomes may be excreted
outside the cell via exocytosis which is present in all cell types [22]. Lysosomes are
translocated towards the plasma membrane via kinesin associated displacement where
it fuses with the membrane and empties its cargo to the outer environment upon the
increase of the internal calcium ions [23]. This specialized organelle is also responsible
for the recycling of free insoluble lipids and M6P receptors back to the trans-Golgi
compartment to be reutilized in different biosynthetic pathways and the trafficking of
more lysosomal enzymes, respectively [18]. Lysosomes can function as a transporter
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vehicle for insoluble lipid catabolites, amino acids, sugars, lipids, and heavy metals
[15]. In addition to its digestive and catabolite function, lysosomes take place in
providing the cell with energy through its membrane [24]. TFEB and mTOR are two
nutrient-sensitive signaling molecules that are translocated to the lysosomal membrane
upon changes in the nutrient status in the cell to activate their downstream signaling
targets to handle the undergoing processes [25]. ATP sensitive Na+ channels are
another source of energy provided by the lysosomal compartments where it has the
capability to sense the extracellular nutrient status and linking energy with it and to
lysosomal membrane potential [26].
Lysosomal adaptation is a sophisticated mechanistic network by which the
lysosome cope with types and amounts of available nutrients at both in vivo and
cellular levels [27]. Lysosomes were thought to be a static organelle until recently with
little influence on cell functions. It was thought that the catabolic activity of the
organelle was dependant on only the rates of the endocytic or autophagic pathways
delivering cargo to lysosomes but such a view has drastically changed after deep
analysis of lysosomes where it has been found that lysosomal function is regulated at
both transcriptional and posttranscriptional levels [28]. Lysosomal function and
adaptation are mainly coordinated and under the control of the coordinated lysosomal
enhancement and regulation (CLEAR) gene network [28]. It includes a cluster of genes
that provides the system with proteins involved in lysosomal biogenesis, autophagy,
endocytosis, exocytosis, phagocytosis, the immune response, and lipid catabolism
[29]. A main key player in the CLEAR network is a helix‐loop‐helix transcription
factor from the leucine zipper family termed as the transcription factor EB (TFEB) [9].
Microarray and gene promoter analyses have shown that many of the CLEAR network
genes share a common motif at which TFEB binds, hence, regulating their expression
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[30]. The lysosomal number and lysosomal enzyme expression are in direct
proportional relation to TFEB expression coordinating lysosomal biogenesis and
function. It also induces lysosomal exocytosis as well as autophagy by activating
autophagosome biogenesis and its fusion to lysosomes [31, 32]. The transcription
factor does not control the basal transcription levels of its related genes but rather
improves their expression levels in responding to environmental signals [30].
1.3.2 Lysosomal enzymes: diversity, trafficking, and functions
The lysosomal lumen contains more than 50 different acidic hydrolases
enzymes that are involved in the degradation of lipids, genetic materials (like the
DNA), proteins, and carbohydrates [2]. Lysosomal enzymes are activated under the
acidic pH of the lysosomal organelle and that is the way by which the cell protects
itself from the nonspecific digestion of its own components in the cytoplasm and other
organelles even if the lysosomal membrane breakdown by chance [17]. Genetic
changes in lysosomal enzyme genes are responsible for more than 30 different
metabolic diseases under the umbrella of lysosomal storage diseases [2].
Lysosomal enzymes are synthesized in the rough ER as part of the secretory
pathway [33]. The nascent polypeptide chain goes through multiple folding steps
through the aid of a group of ER-residing molecular chaperones and acquires a various
number of glycosylation moieties on multiple asparagine residues [34]. Upon their
proper folding, these enzymes will be transported to the cis Golgi network where their
high mannose oligosaccharide chains will be phosphorylated generating a mannose 6
phosphate (M6P) moiety [35]. In the trans-Golgi, lysosomal enzymes carrying M6P
residues will lose their N-acetylglucosamine residues in order for the M6P to be
exposed to facilitate its binding to the M6P receptors expresses on trans-Golgi
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membrane (Figure 2) [36]. Once bound to M6P receptors, bound enzymes will be
taken up via endosomes budded from the trans-Golgi to be transported to lysosomes
by fusion and fission events of the two compartments [36]. Under the lysosomal acidic
environment, lysosomal enzymes detach from their bound receptors that will be
recycled back to Golgi. The acidic pH turns lysosomal enzymes into their mature
active form through various ways that differ from enzyme to another. A minor group
of lysosomal enzymes traffic to lysosomes through M6P receptor-independent
pathways via different receptors like the lysosomal membrane protein LIMP-2 and
sortilin [37, 38]. In addition, a small portion of the synthesized lysosomal enzymes
may get exocytosed to the extracellular milieu where they will be taken back to the
cell via M6P receptors expressed on the plasma membrane via endocytosis to the
lysosomes [39].
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Figure 2: M6P dependent trafficking of lysosomal enzymes
Once they have reached the trans Golgi, newly synthesized enzymes will undergo two consecutive
enzymatic steps (UDP-N-acetylglucosamine 1-phosphotransferase and N-acetylglucosamine-1phosphodiester α-N-acetyl-glucosaminidase delivered from lysosomes via the endosomal pathway)
that aids the M6P residue addition. Image was adapted from Coutinho MF et al [35].

1.3.3 Lysosomal storage diseases: epidemiology, inheritance, and classification
Upon the discovery of lysosomes, Hers and his group reported the first genetic
lysosomal deficiency by complete chance [40]. While studying glycogen storage
disease type II, Hers (1963) was able to identify α-glucosidase where its deficiency
was the reason behind the accumulation of glycogen in various affected tissues. It was
implicated that α-glucosidase lies within the lysosomes due to its need for the acidic
environment to function and hydrolyze its target substrates [41]. He proposed that the
glycogen is internalized into the cell via autophagy where it is directed to lysosomes
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to be digested but due to the absence of its hydrolase enzyme it accumulates in the
diseased cells and tissues which was confirmed later via morphological analysis. Later,
the concept of inborn lysosomal disease, defined as a genetic disorder in which a
lysosomal enzyme deficiency due to a genetic malfunction in the corresponding gene
leads to the accumulation of all related substrates that are normally metabolized by this
enzyme, was adopted in the field [10]. The presented definition implied that a different
lysosomal storage disorder could exist for each enzyme residing in this organelle
which was summarized later in 1971 in a detailed compendium entitled Lysosomes
and Storage Diseases [41].
LSDs are difficult to be clearly defined at the clinical level as there is some
overlap in the symptoms between different disorders that lead to the delay or
misdiagnosing of many cases. As a result, there is a poor LSDs data registry leading
to the difficulty to cover the diseases epidemiologically [42]. Collectively, LSDs have
a prevalence of ∼1/5175 live births worldwide which is extremely rare when compared
to the level of each individual disorder alone [7, 43]. In UAE, LSDs incidence was
found to be relatively high with around 27/100,000 live births among the Emirati
population which was comparable to the data obtained from the Portuguese population
[44, 45]. Although Saudi Arabia shares the same cultural and geographical background
to UAE, LSDs prevalence was relatively higher with a 44/100,000 live births where it
covers around 30% of reported inborn errors of metabolism [46]. Gaucher and Fabry
diseases showed the highest prevalence worldwide with ∼1/75,000 and 1/100,000 live
births [47, 48]. Previous studies have showed that sphingolipidosis (9.8/100,000 live
births) were the most common LSDs in the UAE where GM1-gangiosidosis was
reported

with
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prevalence
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Mucopolysaccharidosis (MPS) constituted the largest subgroup in Saudi Arabia with
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38% of reported cases [44, 46, 49]. Although LSDs are rare disorders, it is relatively
high in the Ashkenazi Jews and Finnish populations who are considered the most
genetically isolated groups [50]. Gaucher disease, Tay Sachs, and Niemann Pick
diseases were reported the highest in Ashkenazi Jews while aspartylglucosaminuria
and neuronal ceroid lipofuscinosis were recorded the highest amongst the Finnish
population [51-53].
Autosomal recessive is the main mode of inheritance in most LSDs except for
Fabry, Hunter, mucopolysaccharidosis type II (MPS II) and Danon disorders which
are X-linked [54]. Despite the extensive study of LSDs so far, finding a straightforward
genotype-phenotype correlation among such a group of diseases is not fully achieved
yet. There is a need to better understand how the nature of different genetic defects
would results in clinical phenotypic variations in LSDs even with patients who are
diagnosed with the same disorder. All types of genetic defects were reported in LSDs
with various outcomes resulting in extreme heterogeneity in symptoms and severity
even within a single disorder [7]. Frameshifts resulted from indels and the insertion of
a premature stop codon by nonsense variants mainly lead to the complete loss of
enzymatic activity in lysosomes because of protein truncation. Functional mRNA
expression of the affected enzyme could be blocked or decrease below the needed
threshold due to splice site variants resulting in complete vanish or undetectable
enzymatic activity [55]. These two types of genetic defects are predicted to cause the
most severe form of any LSD that is accompanied with fast progression of the disease
and may result in low life expectancy in some cases. Missense alterations are very
common in LSDs, but their consequences are the hardest to predict especially when it
comes to understanding its cellular pathogenicity (Figure 3) [7]. Missense variants
effects mainly rely on the change position at the protein level. Amino acid substitutions
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affecting the protein active site function or structure are most properly deleterious
resulting in the complete loss of residual enzymatic activity [3, 4, 56]. If away from
the active site, missense changes may affect the overall folding characteristics or
stability of the affected protein, hence, its possible recognition and retention by the
endoplasmic reticulum (ER) quality control machinery halting its transportation to its
functional organelle. The quantitative loss of the ER retained lysosomal enzyme leads
to the loss in the enzymatic activity in various degrees due to its mislocalization in the
wrong organelle or premature degradation through the proteasomal pathway by
Endoplasmic-reticulum-associated protein degradation (ERAD) [5, 6]. In both
circumstances, the misfolded enzyme does not successfully reach its designated
location to perform its function.

Figure 3: Summary of the major biological implications of point mutations in LSDs
The diagram summarizes the effects of point mutations on lysosomal enzymes’ synthesis, folding, and
activity in forming LSDs. Adapted from Mohamed FE et al [7].

LSDs are considered clinically as a very heterogeneous group of diseases [57].
The group of lysosomal storage diseases was subcategorized into smaller related

15
subgroups based on two main characterizations. First, LSDs were classified into
infantile, juvenile, and adult subcategories based on the disease age of onset and
symptoms severity where the infantile forms are the most severe among the groups
[54]. On the other hand, each disease has a common phenotypic characteristic that
reflects the type of accumulated substrate and its biochemical nature. The substrate
type has been used to classify LSDs into broad groups as summarized in Figure 4 [57].

Figure 4: LSDs classification groups
Lysosomal storage diseases are subcategorized into several groups based on the biochemical type of
the accumulated substrate, integral membrane proteins, lysosome-related organelles (LROs), and posttranslational modification defects.

1.3.4 Clinical characteristics of LSDs
Due to the heterogeneity of LSDs in terms of onset, rate of accumulation,
prognosis, and severity, it is tricky for physicians to early diagnose these diseases in
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affected patients. LSDs diagnosis is primarily based on the physician's expectance of
the patient’s clinical picture [58]. The first line screening is to look for a genetic defect
that may influence any related metabolic pathway that reflects the patient’s presented
clinical symptoms. Once found, the patient will be directed to enzymatic analysis to
confirm the detected genetic defect that could be accompanied by the measurement of
the accumulated substrates in urine, blood, amniotic fluid, and affected fibroblast cells
[59].
LSDs, as mentioned above, are clinically heterogeneous with a wide range of
symptoms that may vary within the same disorder from patient to another. The major
hallmark of all lysosomal storage disorders is the accumulation of unprocessed
substrates within lysosomes of affected tissues leading to cellular dysfunction and
death. The substrate accumulation process will eventually activate a cascade of various
cellular pathogenetic pathways that will lead to multisystemic clinical consequences
[2]. In most of the affected cases, patients will be born with no detectable symptoms
that will start appearing within a window of time differs based on the underlying
genetic defect, affected tissue, and the nature of the unprocessed metabolites [60]. The
classical LSD involves the central nervous system (CNS) symptoms associated with
visceromegaly [57]. Other diseases may show skeletomuscular related defects that
result in a developmental delay in affected children. Other organs may get involved in
multiple LSDs like eye, heart, kidneys, lungs, and spleen. In general LSDs clinical
manifestation can be summarized under four clinical phenotypes based on the site
where the metabolites and substrates are accumulated [61]. Neuronal lipidosis include
neurological regression, seizures, and blindness which are mainly a result of substrate
accumulation in neuronal bodies mainly gray matter of the brain leading to the loss of
neuronal cells and their axons. While storage in the oligodendrocytes and Schwann
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cells (white matter of the brain) lead to leukodystrophy like symptoms that may
include neurological regression, spasticity, and peripheral neuropathy as a result of
myelin loss. Mucopolysaccharidosis symptoms such as visceromegaly, soft tissue
swelling, skeletal dysplasia, and heart disease result from metabolite aggregation in
extraneural tissues. Finally, substrate accumulation in histiocyte cells mostly lead to
storage histiocytosis related clinical manifestations like hepatosplenomegaly, bone
marrow depression, bone damage and other hematopoietic related abnormalities. More
detailed and specified clinical phenotype for GM1-gangliosidosis and Schindler
diseases will be highlighted in coming sections (Chapters 3 and 4).
Physicians and clinical researchers extensively tried to find out a genotypephenotype correlation in LSDs to assist in predicting the upcoming symptoms and its
clinical severity. Severity can be predicted by the amount of residual enzyme activity
detected in the affected individual which reflects the nature of the genetic defect in the
first place. The higher the enzymatic levels the less severe is the form of the disease
due to higher substrates digestion. Disease carriers with heterozygous disease-causing
variants usually don’t show any clinical manifestations as their cells obtain around
50% of the residual activity with the exception of X-linked LSDs like seen in females
with Fabry disease [62]. Destructive genetic defects might result in a complete loss of
functional enzymatic activity leading to a rapid rate of substrate accumulation and
eventually, symptoms will appear at early onset resulting in an infantile or juvenile
form of the disease. In contrast, patients with an adult form usually obtain a relatively
higher residual activity showing less severe clinical manifestations and prognosis as
well as higher life expectancy.
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1.3.5 The pathophysiology underlying LSDs
The main characteristic of all LSDs is the accumulation of different undigested
substrates and metabolites in the lysosomes of various tissues of the affected individual
which will eventually lead to the underlying disease symptoms where the type and
amount of the accumulated substrate determine the disease onset, severity, and
progression. Defects in various pathways or processes like the lysosomal enzymes
production, lysosomal formation, autophagy, and/or lysosome-endosome system may
lead directly or indirectly to the accumulation of the defect linked metabolites in
lysosomes [7]. Genetic defects of all types in the main genes expressing lysosomal
enzymes or its related genes that encodes for lysosomal enzymes’ transporters or cofactors may directly lead to disturb the degradation process of its related substrates,
hence, the occurrence of LSDs. Missense mutations are the most common in LSDs
and their effects are the hardest to predict which will be further highlighted in the next
section [63, 64]. Metabolites aggregates may lead to the activation of the unfolded
protein response in affected cells that will result in the activation of the apoptotic
pathway as noticed in the neural cells in the brains of GM1-gangliosidosis mice [65].
Furthermore, imbalance in the Ca2+ signalling pathways of different organelles
would assist in the formation of several types of LSDs. Ca2+ signalling impairment in
the ER of neuronal cells in Gaucher disease due to the over activation of the organelle
calcium channels is associated with the substrate acculmulation detected resulting in
the high loss of Ca2+ in ER [66]. Also in Sandhoff, Niemann-Pick A and GM1gangliosidosis disorders, a similar effect is seen due to malfunction in the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and inositol 1,4,5-trisphosphategated calcium channels [67, 68]. On the other hand, the impairment in Ca2+
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haemostasis of affected cells’ mitochondria activates the programmed cell death
pathway in GM1-gangliosidosis and Mucolipidosis type IV diseases [68].
As noted earlier, number and size of lysosomes increase in most of LSDs that
will eventually lead to the activation of oxidative stress cascades through the induction
of different reactive species and/or manipulation of the tissue antioxidant capacity
[69]. Oxidative stress is critical due its destructive effect on different cellular
components like lipids, DNA, and proteins that would lead to their inactivation,
induction of membrane instability, and mutations, respectively. It has been reported
that even under enzyme replacement therapy, MPS patients showed notable increase
in the activities of both antioxidant enzymes superoxide dismutase (SOD) and catalase
(CAT) which is an indication of the increase production of reactive oxygen and
nitrogen species due to higher rate of substrate degradation [70]. Although Fabry
patients under enzyme replacement therapy showed similar results, oxidative damage
was also detected in untreated patients as reported by Biancini et al. (2016) [71, 72].
Oxidative stress in Niemann-Pick C (NPC) was used as a biomarker for the disease
onset and severity as well as oxidative stress in NPC fibroblast cells intiated the
activation of the apoptic pathway via the induction of chromogranin A gene [73, 74].
Several other LSDs diseases like Gaucher disease have showed similar effects [75].
Lysosomes are a key player in immunity and containing inflammation. Thus,
abnormal lysosomal function may lead to abnormal autophagy and inadequate
activation of inflammation [76]. In Gaucher disease, macrophages were found to be
overactivated due to the accumulation of glucosylceramide resulting in the release of
different cytokines that will attract other inflammatory cells to the affected cite which
will amplify the underlying inflammation [77]. Moreover, impaired autophagy
detected in Gaucher affected macrophages induce inflammasome activation and the
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release of IL-1β that can be downregulated via molecular chaperone therapy through
enzymatic enhancement [78]. Dysregulation of inflammatory cells has been reported
in multiple LSDs life Fabry disease which showed marked reduction in natural killer
T cells as well as low IL-4 production [79]. Substrate accumulation in many LSDs
may also activate the neuroinflammation process that contribute to neuronal death
[60]. Ceramide accumulation for example trigger the activation of inflammatory
response in neuronal cells via NF-κB release and eventually induce the apoptotic
pathways and glial activation [80, 81]. Loss of glucocerebrosidase activity has also
showed neuroinflammation activation in a Gaucher mouse neuropathy model [82]. The
leakage of cathepsin B and other hydrolases to the neuronal cell cytosol due to
lysosomal membrane disruption triggers inflammasome activation and results in the
activation of the apoptotic pathway [83].
Finally, the formation of metabolites aggregates might lead to the accumulation
of endolysosomes and autophagosomes have been noticed in some LSDs because of
the loss of function of their related lysosomal enzymes. As a result, more substrates
will aggregate and that will eventually cause an impairment in different metabolites
pathways like the sphingolipid pathway [84]. Apoptosis may get activated in many
LSDs due to the accumulation of autophagosomes in affected cells contributing to the
disease pathophysiology. In disease like Neuronal ceroid lipofuscinosis, GM1gangliosidosis, and Niemann–Pick type C disorders, autophagy overactivation has
been

reported

while

in

sulfatase

autophagosome/lysosomes fusion fails [85].

deficiency

and

MPSIIIA

disease

21
1.3.6 Cellular mechanisms and pathophysiology of missense variants causing
LSDs
Missense variant is the change of a single nucleotide in the coding sequence of
a gene resulting in an amino acid substitution in the expressed protein. Point mutations
have various effects on protein function, structure, stability, and interactions with other
proteins [86]. In many LSDs, most of the disease-causing genetic defects reported in
LSDs are from the missense type as reported via the HGMD database [7, 87]. If the
amino acid change occurs in the enzyme active site, it would markedly deteriorate its
functional activity [88]. In contrast, point mutations around the active site may affect
the overall geometry and conformation of such domain which might interfere with the
enzyme binding to its substrate and the overall reaction [89]. Intact substrate binding
sites are very crucial for the enzyme which significantly deteriorates the reaction when
affected by missense changes. Amino acid changes that result in the loss of
functionally critical glycosylation or phosphorylation sites were also reported in LSDs
[7].
As proteins come off the ribosome while synthesis, they fold into its proper
conformation and undergo various post-translational modifications via a diverse set of
ER molecular chaperones [90]. Mistakes while protein synthesis and folding may
occur, but polypeptides with such faults are recognized by the ER quality control
machinery and will eventually be directed towards the proteasomal degradation
pathway. Similarly, misfolded proteins due to amino acid substitutions are tagged in
the ER by its machinery for subsequent aggregation in the ER or degradation via
ERAD (Figure 5) [7]. For ER-resident proteins like lysosomal enzymes, misfolded
proteins will be re-glycosylated by [UDP]-glucose glycoprotein glucosyltransferase to
prolong its interaction with the molecular chaperones calnexin and calreticulin to
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attempt their proper native folding state [91]. The quality control machinery filters out
only the properly folded proteins and allows their exit from the ER via the secretory
pathway [92]. When refolding fails, misfolded proteins will be recognized by
mannose-specific lectins after the cleavage of their terminal mannose residues and will
be tagged for ERAD premature degradation [93]. In properly folded proteins,
hydrophobic domains tend to be buried in the protein core. However, they are exposed
to the outer surface in misfolded proteins that are prone to forming misfolded protein
aggregates in the ER [94]. Whether prematurely degraded or forms aggregates in the
ER, missense mutated lysosomal enzymes will not reach their final destination and
exert a loss of function effect due to their quantitative loss in lysosomes. Although
they are retained in the ER, misfolded lysosomal enzymes may partially retain some
of their enzymatic function [95].

Figure 5: Fate of misfolded proteins in ER
Newly synthesized polypeptides undergo several folding steps via ER resident molecular chaperones
like calnexin. Misfolded folded proteins are recognized by specialized ERAD factors that initiate their
retrotranslocation to the cell cytosol for proteasomal degradation. The image was adapted from
Gonzalez A et al [96].
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1.3.7 Therapeutic approaches of LSDs
Many LSDs have no treatment and patients are provided with only supportive
medications to relieve the underlying symptoms. Understanding the pathophysiology
of these diseases, as well as the molecular pathogenesis at the cellular level, have
helped drastically to propose multiple therapeutic implications to elevate residual
enzymatic activities in affected individuals [7]. In multiple LSDs, 10% of residual
activity is enough to slow the disease progression and improve the patients’ clinical
status through preventing substrate accumulation while 2-3% residual activity was
speculated to result in attenuated form of the disease [97]. Implicated therapeutic
approaches to date are mainly targeting the affected enzyme or the accumulated
substrates. Therapies in LSDs are targeting three main approaches; enzyme
compensation, enzyme enhancement, and substrate reduction (Figure 6).

Figure 6: Summary of current LSDs therapeutic approaches
A) Functional lysosomal enzymes are secreted from transplanted hematopoietic stem cells (bone marrow, peripheral blood, or cord blood) from the donor as the enzyme is
taken up via transmembrane M6P receptors on affected cells where they are trafficked to lysosomes. The normal enzyme breaks down accumulated substrates while captured
receptors are recycled back to the cell membrane. (B) Recombinant enzymes delivered via blood infusion are delivered to lysosomes via the same principle. (C) A wild type
copy of the defected gene is delivered to affected cells via viral vectors ex vivo by manipulating the patients self-cells and transplanting them back to the patient or in vivo by
the direct modification through injecting the patient with the gene vector into the affected tissue or his circulation. (D) Substrate synthesis is reduced using small molecular
inhibitors that bind and inhibit enzymes involved in substrate biosynthesis. Adapted from Mohamed FM et al [7].
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As previously mentioned, lysosomal enzymes that manage to be secreted
extracellularly are captured back to the cell via plasma membrane M6P receptors to be
transported to lysosomes via endosomes [35]. Based on this mechanism, deficient cells
can take up exogenous enzymes via the M6P recapture. Therefore, approaches like
enzyme replacement therapy (ERT), gene therapy, and stem cell transplant can
compensate for the enzymatic loss in affected tissues based on the stated principle. The
first attempt to resolve LSDs symptoms was via hematopoietic stem cell
transplantation (HSCT) where a patient receives processed bone marrow from a
matched donor in order to repopulate cells in the deficient tissue. The new cells will
secrete fully functional enzymes into the blood and extracellular spaces that will be
taken up by deficient cells through M6P receptors expressed on the plasma membrane
[98]. The main principle of this type of therapies in LSDs is the ability of transplanted
cells to contribute to the patient’s affected tissues and repopulate it with new
macrophages carrying the wild type copy of the missing enzyme and becoming a
source of functional enzyme production [99]. In addition, stem cells will aid the
process of cleaning up the accumulated metabolites in affected tissues and help in
reducing inflammation in diseases tissues. It has been thought also that eventually the
donor transplanted cells will replace the patient’s myeloid and microglia in the CNS
making it a possible intervention for affected LSD patients with neurological
manifestations. The main advantage of HSCT is that the recipient will have a lifelong
source of functional enzyme if a full chimerism was achieved. Based on the mentioned
rational, the first attempts of this approach was in the early 80s where it showed
multiple

successful

interventions

in

mucopolysaccharidosis

type

VI

and

Metachromatic leukodystrophy cases [100, 101]. This approach has been limited to
few LSDs like mucopolysaccharidosis I, late-onset Krabbe disease, Sanfilippo
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syndrome, and Wolman disease despite its successful outcomes towards CNS
symptoms due to its safety concerns [102]. The degree of success varies between
different lysosomal storage diseases and even between organs within the same LSD
condition which may be due to the required thresholds for cell engraftment and enzyme
synthesis needed in each disease or affected organ [103]. There are certain selection
criteria for a patient to be considered for HSCT [104]. Not all LSDs respond to HSCT
as some diseases are more sensitive than other as seen in the case of MPS where type
I was found significantly responsive compared to type II from the same disorder.
Successful outcomes have been reported in almost 80% of treated cases with diseases
like MPS type I, adrenoleucodystrophy, metachromatic leucodystrophy, and Krabbe
disease [105]. HSCT is considered a standard care for MPS type I,
Aspartylglucosaminuria, Fucosidosis, Alpha‐Mannosidosis, I-cell disease, Globoid
leukodystrophy,

Metachromatic

leukodystrophy,

Wolman

disease,

and

Adrenoleucodystrophy [106]. Unlike the mentioned diseases, HSCT did not show a
positive enhancement in GM1-gangliosidosis disease even with the milder juvenile
form [107]. HSCT is mostly applied to early diagnosed cases with severe form the
disease which showed undetectable residual activities. Progressive cases are not
applicable because they have already passed the time where their damaged organs
cannot be saved as most of LSDs consequences are irreversible. Early diagnosis
achieved via newborn screening as applied for Krabbe disease (in the US) for example
allow for immediate intervention via early transplantation save the affected child from
neurological damage [108]. Most of the matched patient’s donors are most probably
heterozygous (in autosomal recessive LSDs) for the disease variant making them less
favorable for the procedure. As a proper alternative for bone marrow or peripheral
blood stem cells, umbilical cord blood transplantation (composed of immunologically
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naïve cells) showed more significant enzymatic activity enhancement and full-donor
chimerism as demonstrated by the European Group for Blood and Marrow
Transplantation [109, 110]. In a 2008 study, 159 young patients with different
inherited metabolic disorders including LSDs were followed up for 11 years post cord
blood transplantation [108]. Around 90% of the participants achieved full donor
chimerism and normalized enzyme activities which was more significant than the
previous reported data on bone marrow transplantation and only 8.2% of those patients
showed graft failure. Patients who got HSCT are required for lifetime follow up as the
transplantation is an amelioration procedure and does not completely cure the
underlying disease.
One of the most common and well-implemented therapeutic procedures in the
treatment of LSDs is ERT [111]. Affected individuals are given periodic intravenous
infusions of the deficient enzyme produced and purified via recombinant DNA
technologies. Like HSCT, the recombinant enzyme is endocytosed by diseased cells
through M6P receptors (Figure 6B). ERT is applicable only with soluble enzymes and
that are not membrane bound [57]. The first attempt for ERT was in Gaucher patients
who showed successful enhancement in their clinical status [112]. Childhood or
adulthood ERT administration in Gaucher affected patients showed significant clinical
enhancement allowing them to live a normal life [113]. Then, ERT was implemented
in many other LSDs up to date (FDA approved) like Pompe disease, Fabry disease,
MPS I, II, IV, and lysosomal acid lipase deficiency. It improves the affected patients’
quality of life and alleviates the disease haematological and visceral symptoms.
Patients with Fabry disease showed lower plasma and urine substrate accumulation as
well as improved cardiac, renal functions [114]. Similarly, cardiac and
skeletomuscular symptoms were mitigated in Pompe disease patients who were
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exposed to ERT [115]. The major drawback of ERT is the large size of the recombinant
enzymes that do not diffuse easily into all affected tissues nor the blood-brain barrier.
Therefore, ERT has the low capability to relieve neurological related symptoms which
are the main characteristic of two-thirds of LSDs. There are many current research
efforts to find solutions to overcome the delivery issue by manipulating the
recombinant enzyme with special moieties to ease its fusion into those hard to deliver
tissues.

One-way

is

through

direct

administration

to

the

brain

by

intracerebroventricular administration where the recombinant enzymes are infused
into the cerebrospinal fluid via catheters through the lateral ventricle [116]. ERT is
expensive and increases with the patient’s age because the dose is determined based
on the individual mass. Moreover, ERT is time consuming as the patient under such
therapy requires a lifetime administration but the continuous developments in the field
made it possible to make these administrations weekly or monthly by increasing its
stability [57]. Anaphylaxis and immune reactions in LSDs’ patients undergoing ERT
have been reported which is a major issue in such therapies that may reduce the
effectiveness of the administrated recombinant enzyme [117].
There is extensive research going on gene therapy to be implemented in the
therapy of different monogenic diseases. The principle of this approach is to deliver a
wild type copy of the defective gene to affected cells which is theoretically applicable
in LSDs. Using viral vectors, a wild type copy of the gene can be delivered ex vivo to
the patient’s haematopoietic stem cells or directly to affected tissues in vivo (Figure
6C). The ex vivo administration of the wildtype copy of the gene was the first to be
applied in gene therapy where the patient’s self-cells were genetically manipulated ex
vivo and transplanted back to the patient [118]. Moreover, in vivo administration in
gene therapy is based on the direct injection of the vector carrying the wild copy of the
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gene to the patient’s circulation or affected tissue. Like ERT, the correction of few
cells in an affected tissue would be enough to compensate for the enzyme loss based
on the M6P reuptake principle as 10% regain of residual activity is clinically sufficient
for better clinical prognosis. Viral vectors were more prominent in gene-based therapy
where it showed long-term efficacy. Viruses have the ability to transfer its cargo gene
to multiple cells and tissue types [119]. Viruses like retroviruses, adenoviruses, and
lentivirus have been used in such therapies and showed promising results in LSDs
[120]. Adeno-associated viruses (AAV) on the other hand were more attractive viral
vectors in LSDs due to their potential ability to cross the blood brain barrier and reach
the brain [121]. The main advantage of gene therapies especially compared to HSCT
is that the patient won’t need a donor minimizing the rejection and the adverse effect
of possible development of immune reactions. Self-cells can be genetically modified
and transplanted back to the patient [122]. In HSCT, usually the donors are one of the
matched heterozygous family members who will have only one wild type copy of the
needed gene. In contrast, multiple copies of the gene can genetically engineered and
delivered to the patient [122]. One of the successful stories of gene therapy in LSDs is
with Metachromatic leukodystrophy (MLD) which is a leukodystrophy characterized
by the deficiency of arylsulfatase A enzyme resulting in the accumulation of sulfatides
in multiple cells and tissues mainly in the brain destroying the myelin sheath around
neuronal cells [123]. Treating patients through HSCT if early diagnosed will only slow
the disease prognosis. By gene therapy approach, nine patients with MLD showed an
extensive and stable arylsulfatase A enzyme expression in their brain and other disease
related organs. None of the tested patients showed any related viral toxicity [124]. A
different trial was conducted in an early onset MLD affected children using lentivirus
vector at which the efficacy and the safety of the treatment was assessed [125]. Within
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the first 18 months post-treatment, the preliminary assessment of the treatment showed
promising clinical enhancement and safety of the procedure which will be followed up
for a longer period later that is not reported yet. AAV vector was used in a
mucopolysaccharidosis type IIIA phase I/II trial to deliver both N-sulfoglucosamine
sulfohydrolase enzyme and sulfatase-modifying factor genes [126]. The study was
conducted in four children who got the vector delivered intracerebrally into six brain
sites. No signs of toxicity of the treated children were reported and 3 of the patients
showed high neuropsychological enhancement. An intermediate effect from another
phase I/II trial conducted on Pompe disease patients using AAV based vector was
obtained by direct injection of the vector to the patients’ diaphragms to improve their
respiratory dysfunctions [127]. Gene therapy in animal models of GM1-gangliosidosis
were promising and multiple AVV vectors were effective and safe [128]. But, there
are many challenges to apply gene therapy to human trials of which are the suitable
delivery vector, safety, and the economic cost of the therapy [129]. The first human
clinical trial (NCT04273269) by the NIH was conducted last year using an AVV vector
carrying the GLB1 gene for the treatment of 18 patients with infantile and juvenile
GM1-gangliosidosis [130]. The vector will be applied by intravenous infusion and
patients will be followed up for clinical and safety assessment in the future. Unlike
ERT where a patient requires life-time intravenous infusions to maintain its effect,
HSC gene therapy is a one-time procedure with a long-time effect that saves time and
money [131]. Despite its promising outcomes, the use of viral vectors to induce genetic
modifications has its own safety issues due to its non-specificity that may cause cancer
in the long run or it might induce immune response towards the new expressed enzyme
[132].
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The above therapeutic approaches aim to compensate for the underlying
enzymatic loss in affected cells, but substrate reduction therapy (SRT) is another
strategy to relief the patient’s symptoms by reducing the number of substrate
aggregates in his tissues through the use of inhibitor compounds that interfere with
substrate biosynthesis (Figure 6D) [7]. Miglustat, an SRT compound, has been
approved for the treatment of Gaucher and Niemann–Pick Type C diseases that
showed effective clinical improvements in affected individuals [133]. Many other
compounds are still under study or in clinical trials to be approved in the treatment of
mucopolysaccharidosis, Sandhoff disease, Fabry disease, and Pompe disease [134136]. Unlike recombinant enzymes, SRT inhibitors can diffuse into the hard to deliver
tissues life CNS due to their small molecular weight so extensive studies are ongoing
to accomplish the needed therapeutic aims.
The good understanding of the lysosomal formation, protein folding, and
proteostasis have provided the guide to develop various classes of low molecular size
compounds to enhance protein conformation and folding that will manage the escape
process from ER retention and premature degradation. There are two main classes of
small molecular weight compounds that are in use to restore misfolded lysosomal
enzyme structure and function in LSDs. The first group is pharmaceutical chaperones
(PCs) that aid the stabilization of misfolded enzymes by elevating their cellular levels
and promote their transportation to their distinct functional organelle. PCs are small
compounds that specifically and reversibly bind to their targeted misfolded proteins to
assist their conformational process and increase their stability [7]. PC/misfolded
protein complex is more stable as it has a more favourable free energy in contrast to
free ones at the neutral pH of the ER [137]. Under the acidic conditions of lysosomes,
the PC compound will dissociate from its target misfolded protein to be recycled back

32
to the ER [95]. Pharmaceutical chaperones can be enzyme ligands, agonists and
antagonists, competitive inhibitors, and cofactors (Figure 7). Enzyme enhancement
therapy via PC compounds has been anticipated as a feasible strategy for treating many
LSDs and many compounds have reached phase I/II clinical trials [138]. The first
pharmaceutical chaperone that has proven its effectiveness in LSD treatment was
migalastat hydrochloride (1-deoxygalactonojirimycin) that is an FDA approved
medication for Fabry disease which specifically binds and stabilizes misfolded α-Gal
enhancing its residual activity in affected patients [139]. Due to the ineffectiveness of
ERT in the treatment of GM1-gangliosidosis, different studies have proposed the
synthesis of multiple PCs to enhance the stability and transportation of misfolded βGal that has maintained active site activity. The N-octyl-4-epi-β-valienamine (NOEV),
a valienamine derivative, showed promising enhancement effects on enzymatic
activities in 22 out of 94 different types of GM1-gangliosidosis related missense
mutated β-Gal as well as enhanced the degradation of substrates and showed
significant clinical relieve of the neurological symptoms in murine model of the
disease [140, 141]. 1-deoxygalactonojirimycin (DGJ) and its derivatives have showed
various degrees of enzymatic enhancement in vitro with multiple mutated forms but
some of these compounds showed cross reactivity with other related lysosomal
enzymes. 5N,6S-(N′-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin (6SNBI-DGJ) is an another DGJ derivative that act as competitive inhibitor to β-Gal and
binds to the enzyme to increase its stability. Previous studies have showed significant
enzymatic function improvement in 24 out of 88 β-Gal mutants including four most
common GM1-gangliosidosis variants and revealed the success of this PC to
ameliorated neurological manifestations in mice model [142]. Most importantly to
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mention that, PC chaperoning effects in treating LSDs was found to be mutation
specific.

Figure 7: Pharmaceutical chaperones as a potential therapy for LSDs
Misfolded lysosomal enzymes due to missense mutations are usually retained in ER or prematurely
degraded by the proteasomal apparatus in the cytosol. Once bound to its specific PC compound in the
ER, the misfolded enzyme undergoes proper folding and its stability increases promoting enzyme
transportation to Golgi where it harbors its M6P residue directing the enzyme to lysosome through
M6P receptors where substrates are accumulated. In lysosomes, PC compounds dissociate from
lysosomal enzymes in response to the organelle acidic pH and substrate competition. Adopted from
Mohamed FM et al [7].

The second class of low molecular weight compounds is proteostasis
regulatory (PR) compounds that work by manipulating the proteostasis network in
multiple ways to increase its capacity [7]. They mainly enhance the expression of the
protein molecular chaperones and regulators of the ER quality control machinery
through four different mechanisms [143]. The first class of PRs, including Guanabenz,
manipulate the cellular protein production through global translational inhibition to
decrease the load of molecular chaperones that results in the premature degradation of
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the misfolded protein [144]. In contrast to Guanabenz, Geldanamycin and
Carbamazepine are PR compounds that are used to increase the production of certain
molecular chaperones and modify their function, respectively [145, 146]. At last, some
PR compounds directly manipulate the proteasomal system by enhancing its activity
when cells are under stressful conditions or through the inhibition of the pathways that
lead to protein premature degradation [147].
1.3.8 Iminosugars as pharmaceutical chaperones in the treatment of LSDs
The term “glycomimetics” has been emanated to define a group of artificially
or naturally derived molecules, with shape and polarities resembling carbohydrates
[148]. In short, they structurally manipulated analogues of carbohydrates gives that
chance to mimic carbohydrate activities, but overcome their limitations at the
pharmaceutical level [149]. At the synthetic level, such structural manipulation in
carbohydrates backbone have various promising effects. It can enhance the compound
binding affinity and specificity, increase its bioavailability, manipulate its stability
based on the underlying need, improve its uptake, and delivery [150]. Therefore,
glycomimetics are a rich playground for scientists and biochemists to concentrate on
the design and synthesis of new compounds, which could be used as carbohydrate
analogues with improved performance in the treatment of different diseases of which
lysosomal storage diseases.
Well-known glycomimetics applications are the iminosugars, which are
naturally occurring polyhydroxylated piperidines that resemble monosaccharides
where the ring oxygen atom of the corresponding carbohydrate is replaced by a
nitrogen atom [151]. In the beginning they were known as glycosidase inhibitors due
to their ability in inhibiting glycosidase enzymes. A while later, many compounds were
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found to act as act as immune modulators and chaperones of misfolded proteins
without inhibiting glycosidases [152]. They may also function as antiviral agents,
antidiabetic drugs, and anticancer agents.
Out of more naturally available iminosugars, 1-deoxynojirimycin (DNJ) was
one of a few compounds that caught the attention of scientists for drug discovery and
was the first to be discovered and was originally used in the clinical field for its
antidiabetic properties [153]. Then, the N-butyl form of DNJ (NB-DNJ) was
synthesized, known by its trade name Zavesca, as compound for the treatment of type
I Gaucher’s disease and Niemann–Pick type C disease [152]. It prevents the formation
of substrate aggregates by glucosylceramide synthase which is the main enzyme in the
GSL biosynthesis pathway. In addition to its substrate reduction ability, NB-DNJ
showed chaperoning effect towards glucocerebrosidase enzyme in Gaucher disease
[154]. The detected dual effect of such compound in the treatment of LSDs was a major
advantage in the pharmaceutical industry. Despite its success in the treatment of
multiple LSDs, NB-DNJ showed serious adverse effects on the treated patients [153].
As an alternative compound, Lucerastat, the N-butyl form of 1deoxygalactonojirimycin (DGJ, commercially known as Migalastat), was produced as
a substrate reduction therapy compound that act similarly like NB-DNJ by inhibiting
glucosylceramide synthase enzyme to reduce the load of accumulated substrates [155].
It was originally synthesized for the treatment of Fabry disease then it showed
successful and promising outcomes with Gaucher disease type I and Niemann Pick
disease type C [156, 157]. Lucerastat or NB-DGJ is small molecular weight
iminosugar that has the ability to cross the blood brain barrier and reduce the
accumulation of the underlying substrates in neural cells [158]. Unlike NB-DNJ, NB-
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DGJ is more selective and did not show an inhibitory effects towards the lysosomal
glucocerebrosidase enzyme, hence, it was safer and more tolerable [155].
The migalastat (DGJ) is an orally available iminosugar that behave as a
pharmaceutical chaperone as it acts by stabilizing misfolded α-galactosidase enzyme
due to amenable mutations in Fabry disease [159]. It aids the correction of misfolded
α-galactosidase and promotes its escape from the ER to lysosomes where its activity
is enhanced [139]. Like migalastat (DGJ), its NB-DGJ derivate, in addition to its
substrate inhibitory function, showed a chaperoning effect in multiple LSDs such as
Fabry, and GM1-gangliosidosis diseases [160].
Multiple other pharmaceutical chaperones from the iminosugar class have been
synthesized for the treatment of LSDs. In Schindler disease, 2-acetamido-1,2-dideoxyD-galactonojirimycin

(DGJNAc)

showed

high

specificity

towards

α-N-

acetylgalactosaminidase (α-NAGA) enzyme where its chaperoning effects was around
10 folds higher compared to DGJ [161]. In Gaucher disease, a series of sp2iminosugars showed various chaperoning effects towards glucocerebrosidase enzyme
[162].
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Chapter 2: Methods
2.1 Subjects and Ethical Approval
For the GM1-gangliosidosis case: A five-year-old Emirati male born to a
consanguineous parent was clinically evaluated at the Genetic Metabolic Clinic,
Tawam hospital, Al-Ain, UAE. Skin biopsy was collected from the patient after
obtaining written informed consents from his parents.
For the Schindler disease case: A five-year-old Emirati male born to a
consanguineous couple was evaluated at the Genetic Metabolic Clinic, Tawam
hospital, Al-Ain, UAE. Peripheral blood and a skin biopsy were collected from the
patient after obtaining written informed consents from his parents. Blood samples from
the parents and the proband’s asymptomatic sister were also collected for enzymatic
analysis. Buccal swabs were collected from different family members for variant
screening via Sanger Sequencing.
All procedures performed in studies involving human participants were in
accordance with Al-Ain Medical Human Research Ethics Committee (AMHREC)
according to the national regulations (Approval numbers 10/09 and ERH-2015-3241
15-115) and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards. Samples and images were collected from the patients
after obtaining written informed consents from their parents. Informed consent was
obtained from all individual participants included in the study. Additional informed
consents were obtained from all individual participants for whom identifying
information is included in this article.
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2.2 Chemicals
MG132 and cycloheximide (CHX) (Sigma Aldrich; Cat #: M8699 and C1988,
respectively) were used at 10 μM and 50 mg/ml, respectively. Tunicamycin (Sigma
Aldrich; Cat #: T7765) was used at 5 mg/ml concentration to induce ER stress. NBDGJ was a kind gift from Prof. Francis Platt group (Department of pharmacology,
University of Oxford). NN-DGJ was purchased from Toronto Chemicals, Canada (Cat
#: N649900). Glycerol (Sigma Aldrich; Cat #: G5516) in the rescue analysis was used
at various concentrations (0 – 10%). Curcumin (Cat #: C7727), DMSO (Cat #: D2438),
and thapsigargin (Cat #: T9033) were obtained from Sigma Aldrich.
2.3 Whole Genome Sequencing (WGS)
WGS was performed on HiSeq 4000 platform (illumine) at Centogene lab
(Rostock, Germany) using DNA from the proband and a parent. All potential variants
were analyzed and confirmed by Sanger Sequencing. NAGA and GLB1 gene
transcripts entry (NAGA: ENST00000396398.7 and GLB1: ENST00000307363.10)
and protein sequences (α-NAGA: P17050, and β-Gal: P16278) were retrieved and used
from Ensembl and Uniprot, respectively [163, 164]. The effect of the underlying
variants on protein sequences were predicted via the ExPASy translate tool [165].
Bioinformatics in silico analyses for the NAGA gene variant was carried out
using Mutation Taster, PolyPhen‐2, and SIFT to investigate the possibility of the
variant's pathogenicity [166-168]. Protein conservational analysis for both proteins
was carried out via multiple sequencing alignment among different Eukaryotic species
using protein sequences adapted from the Uniprot database and the conservational logo
for the NAGA protein was generated via Weblogo tool [169, 170]. The HOPE software
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was used to analyze the structural effects of the detected point mutations on β-Gal and
α-NAGA structural and functional nature [171].
2.4 PCR and Sanger Sequencing
Genomic DNA was extracted from blood (Schindler patients and their parents),
and fibroblast cells (GM1-gangliosidosis patient) using FlexiGene DNA extraction kit
(Qiagen) following the manufacturer’s instructions. While it was extracted from
buccal swabs (Schindler patient’s related family members) (Swab collection and DNA
preservation system, NORGEN) using the saliva DNA isolation kit (NORGEN)
following the manufacturer’s instructions. PCR reactions were set for variant presence
conformation and/or segregation analysis in the members of both affected families. On
the other hand, PCR screening of the NAGA gene was performed for family 2 related
family members to screen for the detected variants and results of positive mutations
were included in the family pedigree.
Detected genetic variants were screened via Sanger sequencing. Primers for
exon 4 of GLB1 gene (forward: 5′-TCGGCTGGCTCATGAGCTG-3′ and reverse: 5′TGCAGGAAGCGCAGGTAGTC-3′) and exon 7 of NAGA gene (forward;
5′-CTGCTCATTGGGAACTTTGGTC-3′ and R; 5′-CTTGTGAATCCTGCGTCCC3′) were designed via Primer3Plus and purchased from Metabion Inc. (Germany). PCR
amplifications were carried out on Applied Biosystems Veriti thermal cycler (Applied
Biosystems). 25 μl PCR reactions were prepared to contain 1x PCR buffer (Qiagen
Gmbh), 0.2 mM dNTPs, 5 μM of each forward and reverse primers, 100 ng DNA, and
0.5 U Taq DNA polymerase (Qiagen Gmbh). PCR products were cleaned up using
ExoSAP-IT (USB Inc) followed by Sanger cycle sequencing processing using the
BigDye Terminator kit v3.1 and were run on the 3130x1 Genetic Analyzer System
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(Applied Biosystems, Inc.). Reactions contained 1.5 μl of PCR product, 10 μM of one
of the primers, 5 × BigDye Terminator sequencing buffer, and 1 U of BigDye
terminator Taq polymerase. Sequencing results were analyzed using BioEdit Sequence
Alignment Editor V7.2.5 (Ibis Biosciences, CA).
2.5 White Blood Cells Isolation
Equal volumes of phosphate buffered saline (PBS) were added to each blood
sample (4 ml). Blood/PBS mix was slowly added to an equal volume of Histopaque
1077 (Sigma) and centrifuged at 1500 rpm for 30 min at room temperature. The
peripheral blood mononuclear cell (PMNC) layer was aspirated to a new tube, washed
with PBS, and centrifuged at 1500 rpm for 5 min. Cell pellets were snap frozen and
kept in -80°C for extraction and enzymatic activity measurement.
2.6 Skin Biopsy and Cell Culture
The skin biopsies were washed with 1 × PBS and incubated with 1 mg/ml
collagenase (Sigma) in PBS at 37°C for four hrs. The tissues were transferred to
separate cell culture plates, physically cut into several small pieces and kept in the cell
culture incubator for fibroblast cells to grow in 30% fetal bovine serum
(FBS)/Dulbecco’s Modified Eagle Medium (DMEM; Thermofisher) supplied with
100 U/ml penicillin/streptomycin (Sigma) till confluency. Fibroblast cells were
routinely cultured in DMEM supplemented with 10% FBS, 2 mM l-glutamine (Sigma)
and 100 U/ml penicillin/streptomycin at 37°C with 5% CO2.
For the cell treatment assays in the GM1-gagliosidosis project, patient and
control fibroblast cells were grown in 6-well plates to 70-80% confluency prior to
treatment. Cells were treated with compounds at the indicated concentrations and times
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then harvested and snap frozen for analysis later. For the NB-DGJ 6 days treatment,
culture media was replaced with fresh NB-DGJ containing media at day 3. For
proteasomal inhibition analysis, cells were serum starved overnight prior to CHX
and/or MG132 treatment.
2.7 Enzymatic Activity
PMNC pellets or fibroblast cells from were lysed in 1% Triton X-100 (Sigma)
50 mM tris lysis buffer containing protease inhibitors (Sigma fast protease inhibitor
cocktail, Sigma) and sonicated at low power for 5 s. Total protein was measured using
the BCA protein assay kit (Pierce) according to the manufacturer's instructions. For βGal activity: The reaction was conducted with 10 μg protein lysate in 50 mM sodium
citrate (Sigma) assay buffer, pH 3.5 using 0.8 mM 4-Methylumbelliferyl β-Dgalactopyranoside (Sigma) and stopped with 0.2 N NaOH (Sigma), pH 13 after 2 hrs
incubation at 37°C. For α-Gal activity: The reaction was conducted with 20 μg protein
lysate in 50 mM sodium citrate (Sigma) assay buffer, pH 4 using 2.5 mM 4Methylumbelliferyl α-D-galactopyranoside (Sigma) and stopped with 0.2 N NaOH
(Sigma), pH 13 after 3 hrs incubation at 37°C. Finally, for α-NAGA activity: the
reaction was conducted using 10 μg protein lysate in 50 mM sodium citrate (Sigma)
assay buffer, pH 3.5 using 1.3 mM 4-methylumbelliferyl B-D-galactopyranoside
(Toronto Chemicals) and stopped with 0.2 N NaOH (Sigma), pH 13 after 2-h
incubation at 37°C. Fluorescence was measured using the Infinite® 200 PRO series
fluorescence detector (TECAN) at 360 nm excitation and 455 nm emission.
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2.8 SDS-PAGE Analysis
Patient and control cells were extracted in 1% Triton X-100 lysis buffer and
protein lysates were quantified using BCA kit. 20 µg of fibroblast cell lysates were
boiled in 1x Laemmli sample buffer for 5 min and resolved on 12% SDS-PAGE gel
followed by blotting onto PVDF membranes (Whatman Protran) and co-probed with
anti-human β-Gal or anti- human NAGA antibodies (R&D systems; 1:1000 dilution
for both antibodies) and anti β-actin antibody (Cell Signaling; 1:1000 dilution) as
loading control with the corresponding secondary antibodies. Detection was
performed using Enhanced Chemiluminescence Plus reagent (Pierce) and Typhoon
FLA 9500 Imager (GE Healthcare Biosciences). Images were analyzed for protein
quantification by ImageJ software. Images contrast and background were adjusted
similarly for all images. Using the ImageJ select tool, bands were selected, and band
intensities were translated into histograms that were highlighted. Histogram areas were
quantified by the software and band intensities were translated into numerical values.
The numerical values of the indicated proteins band intensities were then normalized
to the loading control (beta actin). For β-Gal processing and maturation assessment via
western blot, its maturation level was calculated as percentage of total β-Gal protein
expression [mature β-Gal band intensity / (precursor β-Gal band intensity + mature βGal band intensity)].
2.9 Immunoflorescence and Confocal Microscopy Imaging
Patient and control fibroblast cells were grown on coverslips up to 70-80%
confluency a one day before the procedure. Cells were washed with PBS, fixed with
4% paraformaldehyde at room temperature for 10 min followed by methanol at -20°C
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for 5 min. Fixed cells were blocked with 3% bovine serum albumin (Sigma) in PBS
for 1 h at room temperature. After blocking, cells were incubated with anti-NAGA or
anti-β-Gal antibodies (R&D systems) at concentration 1:100 in blocking buffer
overnight at 4°C and co-stained with LAMP1 (Lysosomal marker) and/or calnexin
(ER marker) antibodies at 1:50 dilution (Santa Cruz). Cells were washed to remove
excess antibodies with PBS and incubated with the respective secondary antibodies for
45 min at room temperature, washed three times with PBS and mounted in
immunofluor medium (ICN Biomedicals). Confocal microscopy and imaging were
performed with a Nikon Eclipse system (Nikon Instruments Inc) under 100 × objective
magnification. Images intensities were adjusted only under the microscope and merged
images were produced using ImageJ software. Merged images were zoomed in 4 times
via ImageJ when stated in the figures and scale bars were inserted accordingly.
2.10 Stability and Molecular Dynamics Analysis
For the p.D151Y β-Gal structural and MD simulation analysis: The βgalactosidase crystal structure was obtained from protein data bank (PDB ID: 3WF1)
[172]. The β-galactosidase structure was checked out by MOE and corrected for any
missing atoms via the protein preparation module [173]. The same module was also
employed to assign protonation states and to assign partial charges on the protein
atoms. The D151Y mutation was created by the Residue Scan module in MOE [173].
The previously prepared mutant of β-galactosidase was prepared via XLeap in
AmberTools [174]. All energy minimization and MD simulation processes were
conducted via the pmemd program in Amber12 [174]. Two minimization processes of
1000 steps each were applied where the first process included applying 2 kcal/mol
restraint forces on the protein atoms while the second minimization process was done
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with no restrains at all. The energy-minimized system was heated over 50 ps from 0 to
the desired temperature (300 or 310 K) under NVT conditions where Langevin
thermostat was employed; 2 kcal/mol restraint forces were applied on protein atoms.
Subsequently, density of the system was equilibrated for 100 ps where all protein
atoms were again kept restrained with 2 kcal/mol forces. A total of 200 ns MD
simulations was carried out with coordinates stored every 2 ps. This was conducted at
an average pressure of 1 atm under NPT conditions. With a relaxation time of 2 ps. An
average temperature of 300 K or 310 K was set up and was controlled by Langevin
thermostat (using a collision frequency of 1.0 ps-1). Particle mesh Ewald was employed
to do all explicit solvent calculations, with a cutoff of 10 Å for long-range electrostatics
[175]. The SHAKE algorithm was selected to constrain hydrogen atoms’ covalent
bonds with a time step of 2 fs. Clustering was performed using the ccptraj module in
Ambertools [176]. Frames were previously stripped out of ions and solvent molecules.
Epsilon value was set to 3.
For the p.L280I α-NAGA structural and MD simulation analysis: The NAGA
crystal structure was obtained from the protein data bank (PDB ID: 3H53) [177, 178].
The NAGA structure was corrected for any missing atoms and then protonated via the
protein preparation module in MOE. Consequently, the p.L280I variant was
introduced in the NAGA structure by the Residue Scan module in MOE, which in
return calculates  stability (kcal/mol) for the mutant form as compared with the wild
type. The wild type and mutated NAGA structures were prepared and solvated
separately via XLeap in the AmberTools program. The solvated systems were energy
minimized and simulated (via molecular dynamics) via pmemd in the Amber12
software package. A two-stage minimization process of 1000 steps each was
conducted, with applying 2 kcal/mol restraint forces on the protein atoms only in the
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first stage. The energy-minimized systems were then heated over the time course of
20 ps from 0 to 300 K under NVT conditions using Langevin thermostat and 2 kcal/mol
restraint forces (on protein atoms). Subsequently, the solvated systems’ densities were
equilibrated for 100 ps and using again 2 kcal/mol restrain forces on protein atoms. A
total of 100 ns MD simulations were conducted using an average pressure of 1 atm
under NPT conditions, with a relaxation time of 2 ps. An average temperature of 300
K was set up and was controlled by Langevin thermostat (using a collision frequency
of 1.0 ps-1). The Particle mesh Ewald algorithm was used to conduct all explicit solvent
calculations, with a cut off 10 Å for long-range electrostatics. Hydrogen atoms’
covalent bonds were constrained using the SHAKE algorithm during all MD
simulations. Clustering was performed using the CCPTRAJ module, setting the
Epsilon value to 1.5, after all, frames were stripped out of solvent molecules and ions.
2.11 Real Time PCR
Total RNA was isolated from the patient and control fibroblast cells using
TRIzol Reagent (Life Technologies), precipitated, washed, and eluted using Promega
SV total RNA isolation system (Promega). Total RNA was subjected to reverse
transcription using Promega GoScript reverse transcriptase kit by following the
manufacturer’s instructions. Quantitative real-time PCR was performed on a
QuantStudio 7 Flex (Applied Biosystems) real-time PCR machine. TaqMan real-time
PCR assays (Life Technologies) for XBP-1s (Hs03929085_g1) was used for analyzing
ER stress and as an internal reference control GAPDH (Hs02758991_g1) was used,
according to the manufacturer’s protocol. Gene expression was analyzed by
comparative Ct (∆∆Ct) method using QuantStudio Real-Time PCR software v1.2.
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2.12 IC50 Measurement
Wild-type β-Gal obtained from normal control fibroblast cells’ lysates was
incubated with ascending concentrations of NB-DGJ (0-800 μM) or NN-DGJ (0-40
μM) in sodium citrate assay buffer for 30 min on ice before measuring β-Gal enzymatic
activity as previously mentioned. Activity was blotted in reference to untreated sample
and IC50 of each compound was calculated via Quest Graph™ IC50 Calculator (AAT
Bioquest) (https://www.aatbio.com/tools/ic50-calculator).
2.13 Heat Stabilization Assay
The ability of the PC compounds to enhance β-Gal stability was determined by
incubating 10 µg of normal control fibroblast cell lysates with NB-DGJ or NB-DGJ at
the indicated concentrations in neutral pH buffer tris buffer at 45°C. The enzyme/PC
mixes (20 µl per sample) were incubated on ice for 30 min prior to treatment and
transferred to a 45°C water bath for various time points keeping the T0 sample on ice.
pH of all samples was adjusted to acidic pH by adding 30 µl of 50 mM sodium citrate
β-Gal assay buffer, pH 3.5 then enzymatic analysis were performed as previously
mentioned.
2.14 Glycosphingolipid Profile by HPLC
The protocol was performed as previously mentioned in [179]. Lipids were
extracted from patient and control fibroblast cells using chloroform:methanol (1:2,
v/v) overnight at 4 °C. GSLs were then purified via the use of solid phase C18 columns
(Telos). GSLs samples were dried under a nitrogen stream and ceramides were
digested by glycanase after the elution step to obtain oligosaccharides from GSLs. Free
glycans were then fluorescently tagged with anthranillic acid (2AA). Unbound 2AA
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label was removed out by DPA-6S SPE columns (Supelco). Purified 2AA-labelled
oligosaccharides were separated and quantified by normal phase high-performance
liquid chromatography (NP-HPLC). The NP-HPLC system consisted of a Waters
Alliance 2695 separations module and an in-line Waters 2475 multi λ-fluorescence
detector set at λEx= 360 nm and λEm= 425 nm. The solid phase used was a 4.6 × 250
mm TSK gel-Amide 80 column (Anachem). A standard 2AA-labelled glucose
homopolymer ladder (Ludger) was included to determine the glucose units (GU) of
the HPLC peaks. Individual GSL species were identified by their GU values and
quantified by comparison of integrated peak areas with a known amount of 2AAlabelled BioQuant chitotriose standard (Ludger). Results were normalized to protein
concentrations measured by BCA method.
2.15 Statistical Analysis
Statistical significance was assessed by two‐way analysis of variance
(ANOVA) followed by Tukey's HSD post analysis test via GraphPad Prism 8.0
software. Significance was established at p< 0.05, p < 0.001, and p< 0.0001. In all
graphs, error bars indicate S.E.M, and all experiments were performed in three
biological replicates
2.16 Author Contribution
All molecular analyses mentioned in the thesis were performed by me (Fedah
E. Mohamed) except for the MD protein simulation analysis which was performed by
our collaborators from Al-Ain University (Dr. Mohammad Al Sorkhy and Dr.
Mohamed Ghattas). For the GSL profile, I (Fedah E. Mohamed) have processed the
samples prior injecting it to the HPLC which was handled by Dr. David Priestman at
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the University of Oxford. Patients were examined at Twam Hospital (Al-Ain, UAE)
by Dr. Famta Al Jasmi.
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Chapter 3: N-N-Butyl-Deoxygalactonojirimycin Acts as a
Pharmacological Chaperone and Improves p.D151Y β-galactosidase
Processing and Activity in an Infantile GM1-gangliosidosis Patient’s
Fibroblast Cells
3.1 GM1-gangliosidosis: Inheritance, Types, and Mechanisms
GM1-gangliosidosis (MIM #230500) is an autosomal recessive LSD
associated with genetic defects in the GLB1 gene leading to β-galactosidase (β-Gal;
EC 3.2.1.23) deficiency. The GLB1 gene lies in chromosome 3 at 3p21.33 containing
16 exons spanning 62.5 kb [180]. The gene is responsible for the transcription of βGal enzyme and elastin-binding protein (EBP) via alternative transcription where
exons 3, 4, and 6 are skipped in EBP [180]. EBP is a stretch of 32 amino acids that
takes place in cellular adhesion [181]. β-Gal is a 677 amino acid protein that catalyzes
the removal of the terminal β-linked galactose residue from glycoproteins, keratin
sulfate and sphingolipids [182]. The enzyme is synthesized into the ER as an 88 KDa
precursor that undergoes multiple folding and glycosylation processes reaching its
native properly folded state [183]. Once its signal peptide is lost, β-Gal is directed
toward the Golgi compartment for further post-translational modifications. In the
trans-Golgi, the enzyme harbors an M6P residue on its high mannose oligosaccharide
chain that is essential in its trafficking to lysosomes through M6P receptors on Golgi
membranes. In lysosomes, the high acidic environment will promote the activation
process of β-Gal by initiating the cleavage of the C-terminal 20 amino acids generating
a 64 KDa fully mature form of the enzyme [183].
It is therefore considered a neurodegenerative disorder and is classified into
three clinical subtypes; the severe infantile (type I), the juvenile (type II), and the
milder adult (type III) forms [184]. The severe infantile form is fatal by the age of 1-2
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years and mainly associated with severe progressive neurological symptoms that
manifest during early infancy [185]. Patients with the juvenile form start to show
symptoms at the age of 2-3 years as they retain some residual β-Gal enzymatic activity
compared to those with the infantile form [186]. Type II GM1-gangliosidosis is
associated with slower progression of the neurological related symptoms (ataxia,
seizures, dysarthria, dysphagia, and hypotonia) and life expectancy is relatively higher
as patients may reach late childhood to early adolescence [187]. Finally, type III GM1gangliosidosis is the mildest with late-onset (early to mid-adolescence) of the
symptoms and higher life expectancy. Symptoms are mainly neuromuscular-related
which may result in loss of independent ambulation [184]. Thus far, GM1gangliosidosis has no approved treatment and patients are usually under palliative and
supportive management to relieve the underlying symptoms [185, 187].
In GM1-gangliosidosis, β-Gal dysfunction results mainly in the accumulation
of GM1-gangliosides, in lysosomes of the central nervous system [182, 184]. GM1ganglioside is a crucial component in neuronal cells and found in abundance in these
specialized cells. When accumulated in the affected patient brain and spinal cord, it
promotes global neurodegeneration that is followed by widespread neuroinflammation
[57]. Recent studies have shown that GM-gangliosides also accumulate in the ER
membranes of affected cells activating the unfolded protein response leading to
cellular apoptosis [65]. Accumulated GM1-gangliosides may also affect the
mitochondrial function by interfering with calcium channels at the ER-mitochondrial
membranous contact sites that will promote abnormal calcium flux to the mitochondria
activating the mitochondria-mediated apoptosis [68].
According to the Human Gene Mutation Database (HGMD®), a total of 211
mutations have been reported worldwide in the GLB1 gene of which 152 are
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responsible for GM1 gangliosidosis. Of the 152 mutations, 115 are missense/nonsense
mutations, 13 are splicing mutations, 10 are insertions, and 2 are deletions [188].
Missense variants’ effects are challenging to expect and mainly influenced by the
location of the amino acid substitution at the protein level [189]. As mentioned above,
changes in the enzyme active site are deleterious and most probably will lead to the
complete loss of activity resulting in the severe form of the disease while changes away
from the active site most likely affect protein geometry and structure [56]. Misfolded
lysosomal proteins are recognized and retained by the endoplasmic reticulum (ER)
quality control machinery then directed either for proteasomal degradation via the
ERAD or form aggregates in the ER [86, 189]. In both cases, enzymatic loss of
function is due to the physical loss of the enzyme in lysosomes [56]. Despite of the
disruptive protein conformation resulted from such mutations, misfolded lysosomal
enzymes may not completely lose their functional activity due to an intact active site
[63, 64].
EET has been implicated as a therapeutic approach in GM1-gangliosidosis
using small molecular weight compounds to overcome ER quality control machinery
and facilitate the transportation of misfolded β-Gal [190]. 1-deoxygalactonojirimycin
(DGJ) (Migalastat) is an FDA approved PC compound for the treatment of Fabry
disease prescribed to cases ( ≥16 years mostly from the juvenile and adult forms)
carrying amenable variants that were reported to affect protein conformation and
stability while showed partial functional activity [139]. DGJ is an active site
competitive inhibitor that reversibly binds to misfolded alpha-galactosidase (α-Gal;
E.C. 3.2.1.22) in the ER helping the enzyme to traffic properly to lysosomes [191].
Under the acidic pH of the lysosomes, DGJ dissociates from the enzyme as well as the
availability of the enzyme-substrate in high concentrations in lysosomes aid the
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dissociation process [139]. Different DGJ derivatives have been produced to improve
the compound specificity and affinity to galactosidases [192]. N-butyldeoxygalactonojirimycin (NB-DGJ) and N-nonyl-deoxygalactonojirimycin (NNDGJ) showed promising outcomes in rescuing misfolded β-Gal in GM1-gangliosidosis
in various degrees based on the disease severity and type where the infantile form was
the least responsive to both compounds [193, 194].
In this thesis, an Emirati child was clinically diagnosed with type I (infantile)
GM1-gangliosidosis carrying a previously reported mutation (c.451G>T, p.D151Y) in
the GLB1 gene resulted in a severe β-Gal deficiency. The aim of this thesis was to
delineate the molecular and cellular mechanisms underlying the presented severe
phenotype and evaluate the potentiality of two DGJ derivatives (NB-DGJ and NNDGJ) as PC compounds in rescuing the mutant p.D151Y β-Gal. Molecular and
enzymatic analyses in patient fibroblast cells have revealed that the underlying
mutation affects β-Gal structural conformation, processing, and trafficking hence
explaining the loss of enzymatic activity. Unlike NN-DGJ, NB-DGJ significantly
enhanced the mutated enzyme trafficking and improved its residual enzymatic activity.
These data indicate the potentiality of PC compounds to facilitate the proper trafficking
of the misfolded β-Gal enzyme in infantile form GM1-gangliosidosis if the detected
cellular defect is amenable.
3.2 Results
3.2.1 In silico characterization of c.451G>T missense variant detected from whole
genome sequencing in the GLB1 gene of the patient
An Emirati male child from a consanguineous parent was admitted to the
genetics clinic and clinically diagnosed with the infantile (type I) form of GM1gangliosidosis. The family had a previous history of the disease as they have lost two
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children with the same disease. A five years old male child passed away suffering from
brain atrophy, asthma and feeding problems and an eleven years old female child who
was lost due to carbon monoxide poisoning. At three years old, the girl started to lose
her milestones and suffered from seizures, severe gastroesophageal reflux, spastic
palsy, mitral valve regurgitation, hypertension and asthma. On the other hand, the child
included in the current case was reported to have global developmental delay, muscle
atrophy, and regression with spasticity in upper and lower limbs, constipation,
scoliosis, and recurrent upper respiratory tract infections (URTIs). Medically
uncontrolled generalized and focal seizures, speech problems, and failure to thrive. A
percutaneous endoscopic gastrostomy (PEG) tube was inserted on for the patient on
November/2014. Currently, the patient is under palliative medications for seizures and
constipation, followed by a physiotherapist and dietitian to maintain his weight.
Whole genome analysis, performed in the clinic, reported a previously known
homozygous missense variant (HGMD CM042715) in Exon 4 at position 451
(c.451G>T) of the GLB1 gene. Through Sanger Sequencing, exon 4 of the GLB1 gene
from patient and control fibroblast cells genomic DNA was sequenced to confirm the
homozygous presence of the variant in the patient gene (Figure 8a). At the protein
level, the detected missense variant results in a point mutation at where the wild type
aspartic acid at position 151 is substituted with a tyrosine (Figure 8b). The wild type
aspartic acid was found to be highly conservative among multiple eukaryotic species
as revealed through the conservational analysis performed by multiple sequence
alignment, hence, its importance of this residue for the enzyme function and/or
conformation (Figure 8c).

Figure 8: In silico analyses of c.451G>T missense variant in type I GM1-gangliosidosis patient fibroblast
a) Chromatogram of exon 4 of the GLB1 gene around the detected missense variant preformed via Sanger Sequencing. Genomic DNA was extracted from patient and control
fibroblast cells, exon 4 was amplified via PCR, and sequenced by Sanger Sequencing. The upper panel in the chromatogram represents the wild type nucleotide sequence
around the mutation site at position 451 where the wild type G is substituted to T in a homozygous state as shown in the patient chromatogram (lower panel) b) The
consequence of c.415G>T missense genetic change on the β-Gal enzyme amino acid sequence. Mutated β-Gal amino acid sequence was generated using the ExPASy online
translating tool c) Conservational analysis via Clustal Omega of β-Gal protein sequence around the mutated amino acid among different eukaryotic species. Protein sequences
were obtained from Uniprot database as highlighted in the material and methods section.
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3.2.2 The p.D151Y substitution variant leads to drastic structural disturbance in
the β-Gal enzyme conformation as revealed by molecular dynamic analysis
Figure 9 is schematic illustration of the enzyme main domains and critical
structural residues important to the enzyme function and structure. The enzyme is
synthesized from a pre-proprotein of 677 amino acids of which is a 23 amino acids Nterminal signal peptide that will be cleaved off upon the protein transportation into the
ER [1]. The pro-peptide β-Gal enzyme is composed of three main domains which are
the TIM barrel, β-domain 1, and β-domain 2 [2]. The β-Gal protein harbors seven
glycosylation sites most of which are in the C-terminal part in the β-domains (Figure
9, red circles). The TIM barrel domain was found similar to the domains in the
enzymes that belong to the glycoside hydrolase family 35 based on protein sequence
similarities [2]. The enzyme catalytic nucleophile and acid/base catalyst are residing
in the β-Gal TIM barrel domain at positions E268 and E188, respectively (Figure 9,
brown arrows). Also, the domain contains the four substrate binding sites at positions
83, 129, 187, and 333 (red arrows in Figure 9). Although the amino acid substitution
detected in the patient β-Gal lies within the TIM barrel domain, it is located relatively
far away from the active site residues of the enzyme (highlighted in yellow in Figure
9). According to computational prediction using the HOPE software, the wild type
Asp151 was found in contact with four different amino acids with hydrogen-bonds
(K142, L146, D153, and D154) and a salt bridge with K142. The stated amino acid
interactions might be an indication to the amino acid importance to the enzyme
structure that will be highlighted further in the coming MD simulation analysis.
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Figure 9: Schematic illustration of the human β-Gal enzyme
The protein signal peptide (SP), domains, and subunits are illustrated. Mutated aspartic acid
highlighted in yellow, N-glycosylation sites in red circles, catalytic residues composing the protein
active site presented in orange stars, and the enzyme substrate binding sites in red arrows. Amino
acids which are in contact with D151 through hydrogen bonds and salt bridge are presented as blue
and green arrows, respectively.

The amino acid substitution is predicted to be critical due to the obvious
structural and chemical differences between the two amino acids. Aspartic acid is
negatively charged with a relatively smaller R-chain in contrast to the aromatic neutral
side chain of tyrosine that increases its hydrophobicity (Figure 10a). Overall, D151 is
favorably found in a turn that lies directly before the eighth α-helix and located on the
surface face of the protein exposed to the outer surroundings (Figure 10b). However,
the mutated tyrosine is favorably found in the protein cores due to its hydrophobicity.
Therefore, the amino acid change is likely to affect the enzyme overall tertiary
structure and conformation.
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Figure 10: p.D151Y predicted effect at the structural level
a) schematic structures of the original (green) and the mutant (red) amino acid superimposed over
each other adapted from the HOPE prediction tool b) Asp151 at the α3 of β-Gal. Image was adapted
from the PDB data base (3THD).

In addition, the MD simulation presented in table 1 shows that the mutated
form of β-Gal enzyme is considerably different when compared to the wild type
conformation, showing as high backbone RMSD as 3.3 Å. The most critical shift in
the secondary structure was shown by the backbone of the Lys142-containing loop
which had an RMSD value of 4.1 Å. Figure 11 shows the β-Gal structure of the wild
type and mutant form (obtained from MD simulations) along with few relevant
residues. As demonstrated in the figure below, Asp151 is normally set to build a salt
bridge with the Lys142 side chain, however, it loses this interaction when mutated to
Tyr. As a result, Lys142 shows a significant shift by 10.25 Å as it forms a salt bridge
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with the subsequent aspartate residue situated at position 153. Hence, the mutation of
the concerned aspartate residue seems to have significant consequence on the overall
structure of β-galactosidase and that might explain its enzymatic malfunction at
cellular level.

Table 1: The RMS difference between the superimposed enzymes (wild type &
mutated)
Maximum
RMSD Type

RMSD (Å)
distance*(Å)

Backbone RMSD

3.2920

6.7170

Backbone RMSD-including beta carbons

3.3505

6.9285

Backbone RMSD-excluding Oxygens

3.2601

6.7170

Side chain RMSD

4.5722

10.2307

Side chain RMSD-excluding beta carbons

4.6626

10.2307

Entire lysine142 loop RMSD

4.1748

10.2307

Lysine142 RMSD

6.2792

10.2307

*maximum distance between the atoms of the most different atom pair.
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Figure 11: p.D151Y MD simulation analysis
The crystal structure of β-galactosidase (blue cartoon) is aligned on the mutated structure (red cartoon)
resulted from 200 ns MD simulations. Asp151 and its corresponding mutant residue (Tyr) along with
Lys142 are shown in the ball and stick form.

3.2.3 Patient’s fibroblast cells are highly deficient of β-Gal enzymatic activity with
less than 1% of normal control cells.
To confirm the loss of function effect of the detected genetic defect at the
functional level, a β-Gal florescence-based assay was optimized using normal control
fibroblast cells’ protein extracts. An in-house 4-methylumbelliferone (4-MU)
florescence based enzymatic activity protocol has been optimized to be used through
the whole study. Standard curve has been blotted using 0-6 µmol/l 4-MU dilutions in
stop buffer (0.2 NaOH, pH 13) (Figure 12a). For enzymatic analyses, fibroblast cells
were harvested in mild 0.1% triton X-100 lysis buffer and cells were sonicated for 5
seconds at low plus power. First, multiple protein lysate amounts ranging from 0-20
µg have been incubated with 0.8 mmol/l 4-Methylumbelliferyl β-D-galactopyranoside
substrate at 37°C for 2 hrs. The reaction was stopped with 900 µl of 0.2M NaOH (pH
13). Readings were within the linear range from 2 to 15 µg protein lysates (Figure
12c). Based on the previous analysis, 10 μg protein lysates were incubated with 0.8
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mmol/l β-Gal substrate at 37°C for different time points up to 4 hrs. Florescence
signals were within the linear range from 1 to 4 hrs (Figure 12b). Finally, different
enzyme substrate amounts (0-1.6 mmol/l) were incubated with 10 µg protein lysate for
2 hrs at 37°C. Enzymatic activity was stable from 0.8 to 1.6 mmol/l of substrate (Figure
12d). Overall, for the following β-Gal enzymatic activity assays 10 µg lysates were
incubated with 0.8 mmol/l substrate for 2 hrs at 37°C. The reaction was stopped with
900 µl 0.2 M NaOH stop buffer and florescence was read at 360 nm excitation and
445 nm emission and corrected with the blank reading. 4-MU concentrations in
samples were measured using the generated standard curve and normalized to the
amount of protein and incubation time to calculate β-Gal activity in µmol/ hr/ mg.
Using patient fibroblast cells’ lysate, there was almost a complete loss of β-Gal
activity in patient fibroblast cells with 6 nmol/hr/mg compared to 7957 nmol/ hr/ mg
in control sample which is less than 1% of control activity (Figure 13). The obtained
activity is correlated with the patient clinical presentation and the severity of the
presented symptoms.

Figure 12: β-Gal enzymatic assay optimization
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a) 4-MU standard curve b) Incubation time optimization blot. 10 µg lysates were incubated with 0.8 mmol/l 4-MU tagged substrate and florescence were measured at different
time points (0-4 hrs) c) Lysate amount optimization blot. Protein lysates (0-20 µg) extracted from control fibroblast cells were incubated with 0.8 mmol/l 4-MU tagged
substrate for 2 hrs. d) β-Gal substrate optimization blot. 10 µg lysates were incubated with different substrate amounts (0-1.6 mmol/l) and florescence readings were taken
after 2 hrs incubation. All analyses have been performed in duplicate, repeated three times, and standard errors were calculated.
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Figure 13: β-Gal activity in control and patient fibroblast cells
10 µg of cell extracts of control and patient fibroblast cells were incubated with 0.8 mmol/l 4-MU
tagged substrate at 37°C for 2 hrs. Florescence intensity were measured at 360 nm excitation and 445
nm emission. Florescence readings were normalized to 4-MU standard curve, protein concentration,
and incubation time. The presented readings are the mean of three independent repeats.

3.2.4 p.D151Y β-Gal was found to be retained in the ER leading to its quantitative
loss in lysosomes
To further delineate the underlying mechanisms the loss of enzymatic
functionality detected in patient cells, p.D151Y β-Gal processing and localization were
analyzed in fibroblasts from the patient. In cells from healthy individuals, β-Gal
enzyme is synthesized as a precursor enzyme form in the ER with an 88 KDa size that
go through multiple folding and glycosylation steps to reach its native structural state
as mentioned previously in more details in the introduction section [183]. Upon the
cleavage of its N-terminal signal peptide, β-Gal precursor protein is trafficked to the
Golgi compartment for further post-translational and folding modifications. In the
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trans-Golgi, β-Gal is labeled with a M6P residue on its high mannose oligosaccharide
chain that will mark the correctly folded enzyme for M6P receptor dependent
transportation to lysosomes. Once in the acidic organelles, the acidic pH of the
lysosomes will activate the enzyme maturation process by cleaving 20 amino acids of
its C-terminal end generating a 64 KDa mature active form of β-Gal enzyme. In SDSPAGE analysis, the wild type enzyme runs as two bands in reducing conditions
representing the precursor and mature forms at 88 and 64 KDa sizes, respectively
(Figure 14a). In contract, the 64 KDa mature form of p.D151Y β-Gal was almost
completely lost in patient’s fibroblast lysates which is an indication of improper
processing and maturation of the mutated form of the enzyme (Figure 14a, right lane).
Quantitative analysis of the obtained SDS-PAGE blots revealed that normally around
70% of total β-Gal enzyme in expressed as its mature form in fibroblast cells which
was 4.5 time less in GM1 fibroblast cells with ~15% of total β-Gal expression (Figure
14b). It is quite noticeable to mention that the precursor expression levels in GM1
affected cells were higher compared to normal control which might be mainly due to
its retention in the ER and prolonged half-life. To further confirm the misprocessing
and ER retention of the enzyme, β-Gal colocalization assay was performed via
immunoflorescence (IF) staining (Figure 14d). In normal control fibroblast cells, wild
type β-Gal mainly shows a punctum like staining pattern in IF analysis representing
the lysosomal staining pattern which was not detected in patient cells that showed more
of mesh like pattern spreading around the nuclear region. For colocalization analysis,
both normal and GM1 affected cells were co-stained with calnexin and LAMP1
markers that represent an ER or lysosomal colocalizations, respectively. Wild type βGal in normal control fibroblast cells shows normal colocalization with LAMP1 the
lysosomal marker while p.D151Y β-Gal was mainly colocalized with the ER

64
(calnexin) marker (Figure 14d). In conclusion, p.D151Y β-Gal has improper
trafficking and processing where it is trapped in the ER as showed by the IF staining.

Figure 14: D151Y β-Gal has improper processing and maturation and ER trapped
a) p.D151Y β-Gal enzymatic processing to its mature form is impaired. 15 µg patient and normal
control fibroblast total protein lysates were subjected to SDS-PAGE analysis and stained with an antiGLB1 specific antibody. Beta-actin was used as a loading control b) β-Gal maturation level
quantification. Mature β-Gal expression (western blot bands) was quantified and normalized to betaactin. The bar graph is presenting the mature enzymatic form expression relative to total β-Gal
expression. Presented SDS-PAGE and IF analyses are a representation of three independent repeats. c)
Colocalization analysis of the wild type and mutated β-Gal via IF where β-Gal is co-stained in green
with calnexin (ER marker) or LAMP1 (lysosomal marker) in red. Composite images and SDS-PAGE
quantification were generated via ImageJ software.
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Figure 14. D151Y β-Gal has improper processing and maturation and ER trapped
(continued)
a) p.D151Y β-Gal enzymatic processing to its mature form is impaired. 15 µg patient and normal
control fibroblast total protein lysates were subjected to SDS-PAGE analysis and stained with an antiGLB1 specific antibody. Beta-actin was used as a loading control b) β-Gal maturation level
quantification. Mature β-Gal expression (western blot bands) was quantified and normalized to betaactin. The bar graph is presenting the mature enzymatic form expression relative to total β-Gal
expression. Presented SDS-PAGE and IF analyses are a representation of three independent repeats. c)
Colocalization analysis of the wild type and mutated β-Gal via IF where β-Gal is co-stained in green
with calnexin (ER marker) or LAMP1 (lysosomal marker) in red. Composite images and SDS-PAGE
quantification were generated via ImageJ software.
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3.2.5 ER-retained p.D151Y β-Gal is not directed towards proteasomal
degradation via the ERAD machinery
As part of the cellular hemostasis, if a misfolded protein fails to properly refold,
it will be recognized by the ERAD machinery and directed towards one of two paths.
It will either be tagged with monoubiquitin molecules via ER-associated E3 ubiquitin
ligase and retro-translocated to the cytoplasm for proteasomal degradation or if the cell
has the capacity to handle the ER-retained complex, the misfolded protein will initiate
the formation of aggregates in in the ER. The wild type enzyme in normal control
cells usually takes a bit less than 8 hrs to convert ~50% of its precursor form to the
mature form, in contrast to the mutated β-Gal in affected cells which appear to remain
within the same level at the same time point (Figure 15a and 15b). At 16 hrs, mutated
precursor β-Gal expression levels decreased about 50% compared to untreated sample
with not sign of any increase in the expression levels of its mature form. To figure out
the fate of the misfolded p.D151Y β-Gal, the proteasomal machinery was inhibited in
patient fibroblast cells with 10 uM MG132 for 16 and 24 hrs in the presence of the
protein translational inhibitor cycloheximide (CHX) (Figure 15c). The precursor form
of p.D151Y β-Gal expression level was not significantly changed upon the two time
points of the inhibition treatments (Figure 15d).
3.2.6 Mutated β-Gal ER-aggregates do not exert ER stress in patient’s fibroblast
cells
When misfolded protein aggregates exceed the ER capacity, ER stress is
provoked as a trigger for the unfolded protein response activation. ER stress activation
can be measured by the XBP1 transcription factor expression via RT-PCR. In patient
cells, XBP1 expression levels were within the same range as in normal control
compared to the tunicamycin (ER stress trigger) treated cells (~70 folds increase)
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(Figure 15e). In conclusion, p.D151Y β-Gal is not directed to premature degradation
via the proteasomal pathway and accumulates in the ER.

Figure 15: Retained p.D151Y β-Gal is prone to aggregate in the ER and didn’t exert
ER stress in patient’s fibroblast cells
a) Cycloheximide chase assay for β-Gal in control and GM1 patient fibroblast cell. Cells were serum
starved for 6 hrs followed by CHX treatment for stated time points. SDS-PAGE was performed using
15 μg total lysates to check precursor β-Gal expression b) Quantitative analysis of the CHX chase blot
using ImageJ software. Expression levels were expressed at % of untreated sample c) Effect of
proteasomal inhibition on mutated β-Gal expression. Patient fibroblast cells were treated with CHX in
the presence of 10 µM MG132 proteasomal inhibitor for the indicated time points. Total cell lysates
were analyzed by immunoblotting against β-Gal. Precursor β-Gal relative expressions were quantified
a normalized to β-actin levels. Regions cropped from separate images are demarcated with borders. d)
Graph representing the relative mean densities of precursor β-Gal at 16 and 24 hrs time-points. Actin
normalized untreated precursor β-Gal levels at 0 h were defined as 1.0 for each panel. Error bars
represent SEM from n = 3 independent experiments. e) ER stress induction in patient fibroblast cells.
XBP-1 transcript levels were measured through quantitative PCR (qPCR). The XBP-1s mRNA level
in control fibroblast cells was set as 1.00. Fold-changes mRNA expression of tunicamycin treated
control cells and patient cells were expressed in relation to untreated normal control. Error bars
represent ± S.E.M. of three independent experiments; (**) p< 0.005.
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3.2.7 Patient fibroblast cells did not show substrate accumulation of both GM1gangliosides or keratan sulfate
In LSDs, the main characterization of such disease is the accumulation of the
defected enzyme’s related substrates in the lysosomes of affected cells and tissues.
Diseases’ symptoms are directly linked to the accumulation of these substrates that
lead to the activation of a cascade of cellular pathways including the unfolded protein
response and ER stress that will eventually results in cell death via apoptosis or
autophagy [57]. In GM1-gangliosidosis, the main reported substrate that accumulate
in patients’ tissues are the GM1-gangliosides. Such molecules are mainly expressed in
neuronal and CNS cells where they are a key player in many cellular processes like
differentiation, memory, signaling transduction, cellular protection, neuronal
recovery, and cellular death via apoptosis [195]. Based on that, a full
glycosphingolipid profile via HPLC analysis was performed in normal and patient
fibroblast cells in order to be used as an assessment parameter for the p.D151Y β-Gal
rescue analyses in addition to the other molecular assays. Cells were harvested at 8090% confluency and lysed in PBS by freeze/thaw cycles. Using total cellular lysates,
GSLs were pulled down via chloroform/methanol method, eluted via a hydrophobic
C18 column in chloroform/methanol mix, and evaporated via nitrogen steam. GSLs
were treated with a recombinant endoglycoceramidase (rEGCase) enzyme to digest
out the ceramide residues from the oligosaccharides. Free saccharides were 2Aminobenzoic acid (2-AA) labeled and eluted in water through DPA-6S amide
columns. Samples were applied to HPLC along with 2AA-Chitotriose calibration
standard. Readings were normalized to total protein concentration. The patient’s
fibroblast cells which are included in this study did not show any GM1 ganglioside
accumulation (levels were like that in normal control), so this type of rescue
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assessment is not applicable for the presented case (Figure 16). Keratan sulfate is
another main substrate of β-Gal enzyme but it was shown to be accumulated in
patient’s affected with Morquie B disease of GLB1 diseases. Although it was not
linked to GM1-gangliosidosis disease, keratan sulfate was measured in patient
fibroblast cells using an ELISA based assay which did not show any significant change
compared to that detected from normal control cells (data not shown).

Figure 16: Glycosphingolipids profile in GM1 patient and normal control fibroblast cells performed via HPLC
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a) GSL profile performed by HPLC b) zoom in at GM1 ganglioside HPLC resulted peaks c) bar graph representation of normalized quantification of the HPLC florescence
readings to nmol/mg protein
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3.2.8 Glycerol treatment and/or reduced temperature partially stimulate β-Gal
maturation and correct trafficking to lysosomes in patient fibroblast cells
Chemical chaperones are nonspecific compounds that manipulate the
surrounding solvent conditions by sequestering water molecules around misfolded
proteins to enhance their folding in a hydrophobic environment [137]. Compounds like
glycerol, DMSO, and thapsigargin act as chemical chaperones but the nonspecific
effect of such compounds may show some cellular toxicity to the treated cells though
as primarily analysis of the mentioned compounds has been used to check whether the
mutated β-Gal has the potentiality for rescue from the ER quality control machinery
[196]. Curcumin on the other hand, manipulates the function of ER resident molecular
chaperones where it was able to abrogate ER retention and aggregation in multiple
conformational diseases [197]. From all the four mentioned compounds, glycerol
showed marked increase in the maturation and processing of mutated β-Gal in patient
fibroblast cells (Figure 17).
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Figure 17: Chemical chaperones screening for p.D151Y β-Gal rescue analysis
Patient fibroblast cells were treated with different chemical chaperones (7.5% glycerol, 1% DMSO,
1mM curcumin, and 5 mM thapsigargin for 3 days. 15 ug of total protein lysates were blotted for βGal enzyme.

Glycerol is an osmolyte which behave as a chemical chaperone that promotes
the correct folding of a misfolded protein favoring the formation of the polypeptide in
its native state [198]. Glycerol suppresses the formation of protein aggregates through
stabilizing and inhibiting protein unfolding by favoring the interactions between the
misfolded enzyme hydrophobic surface residues and the amphiphilic interface
orientations of glycerol [198]. The use of glycerol as a chemical chaperone has been
implemented in various published studies with misfolded proteins retained in the ER
due to missense defects in order to promote their correct trafficking [5, 199, 200].
Some forms of point mutation may affect protein structure and folding through the
change in its thermodynamic properties decreasing its overall stability. Like glycerol,
culturing affected cells under low temperature helps to correct the conformation,
hence, its trafficking, through manipulating its thermodynamic properties [200]. In the
current study, GM1 fibroblast cells were treated with ascending concentrations of
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glycerol at normal (37°C) and reduced temperature (27°C) for 3 constitutive days.
Both glycerol and low temperature alone or combined showed various enhancement
effects on mutated β-Gal enzyme (Figure 18). The p.D151Y β-Gal processing and
maturation was improved via glycerol treatment where the mature form expression
was increased in a concentration dependent manner (Figure 18a). The maturation level
(% of total β-Gal) of p.D151Y β-Gal enzyme significantly increased under the high
range concentrations of glycerol reaching up to ~35.6% of total β-Gal expression at
10% glycerol which was equivalent to ~5 folds increase compared to untreated cells
(Figure 18b).

Interestingly, low temperature alone elevated p.D151Y β-Gal

maturation level almost up to 8 folds higher than untreated GM1 patient cells reaching
up to ~54% of total β-Gal expression (Figure 18a and b). However, glycerol effect
under reduced temperature was not only hindered but also the mature enzymatic
expression was decreasing in a concentration dependent manner (Figure 18b). At
reduced temperature, different cellular processes like proliferation are usually slowed
down making it harder on the cells to cope with the glycerol toxic effect and
compensate for the cellular loss under high concentrations.
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Figure 18: Glycerol and low temperature promote p.D151Y β-Gal processing and
maturation
a) SDS-PAGE of 15 µg patient and control fibroblast cell lysates treated with increasing glycerol
concentrations at 37°C and 27°C for 72 hrs. β-Gal bands were quantified and normalized to beta-actin
via ImageJ software. b) Bar graph representing p.D151Y β-Gal maturation levels (% of total β-Gal
expression) under the specified conditions. Error bars are representation of three independent
experiments. ** p < 0.005, *** p < 0.0005, and #### p < 0.0001; p-values were calculated via the
two-way ANOVA followed by Tukey's post-analysis using the means of absolute β-Gal activity
values in comparison to untreated patient sample.

Patient fibroblast cells were cultured under the previous mentioned conditions
and processed for IF staining to analyze the effect of glycerol and low temperature on
the mutated enzyme trafficking and localization. Similarly, glycerol promoted
p.D151Y β-Gal enzyme transportation at various degrees where 8% glycerol was more
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effective compared to the lower concentrations used (Figure 19). On the other hand,
low temperature exhibited better performance in β-Gal trafficking showing more
prominent puncta-like staining colocalized with the lysosomal marker LAMP1
indicating a better enhancement effect that was debilitated under glycerol treatment
(Figure 20). It is clearly notable that glycerol treated cells treated cultured under low
temperature lost their proper cellular structure in contrast to those cultured under
normal temperature that might explain the reason behind the loss of the enhancement
of the glycerol effect at 27°C (Figure 19 and Figure 20). At 10% of glycerol, fibroblast
cells were almost completely dead and structurally corrupted due to glycerol high
toxicity.
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Figure 19: Glycerol promotes p.D151Y β-Gal trafficking to lysosomes
Patient fibroblast cells were grown on coverslips and treated with increasing amount of glycerol (0 –
8%). After 72 hrs, cells were fixed with 4-PFA, permeabilized with methanol, and co-stained for βGal (green) and organelle marker (red) (calnexin; ER marker or LAMP1; lysosomal marker). Images
were captured via Nikon confocal microscopy at 100x. Images were merged and zoomed via ImageJ
software.
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Figure 20: The p.D151Y β-Gal trafficking is markedly enhanced in patient cells
under reduced temperature
Patient fibroblast cells were grown on coverslips and treated with increasing amount of glycerol (0 –
8%). After 72 hrs incubation at 27oC, cells were fixed with 4-PFA, permeabilized with methanol, and
co-stained for β-Gal (green) and organelle marker (red) (calnexin; ER marker or LAMP1; lysosomal
marker). Images were captured via Nikon confocal microscopy at 100x. Images were merged and
zoomed via ImageJ software.
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3.2.9 The p.D151Y point mutation is an amenable GM1-gangliosidosis variant
where its activity was significantly enhanced under glycerol and reduced
temperature
Glycerol and reduced temperature influence on enzymatic activity was
compatible to that detected from the protein processing and trafficking assays (Figure
21). Likewise, glycerol elevated p.D151Y β-Gal residual enzymatic activity in a
concentration dependent manner at 37°C reaching up to ~2.3 folds increase compared
to that detected in untreated cells (~1% of normal control β-Gal activity) (Figure 21a).
At reduced temperature, β-Gal enzymatic activity reached up to ~7 folds increase that
is equivalent to ~2.5% of wild type β-Gal activity in normal control (Figure 21b).
Again, glycerol under reduced temperature did not show significantly synergistic
effect on β-Gal activity in treated patient fibroblast cells.
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Figure 21: The p.D151Y β-Gal activity is enhanced via glycerol and low temperature
Patient fibroblast cells were treated with increasing glycerol concentrations (0-8%) for 72 hrs at 37°C
and 27°C temperatures. β-Gal activity was performed with 10 μg of cell lysates and data were
presented as a) percentage of normal β-Gal activity in normal control fibroblast cells and b) fold
change of β-Gal enzymatic activity in patient’s untreated cells. Error bars represent ± S.E.M. of three
independent experiments. (*) p< 0.05 and (####) p< 0.0001; two-way ANOVA followed by Tukey's
post-analysis.

3.2.10 MD simulation analysis showed that p.D151Y β-Gal retained better
thermal stability under reduced temperature
MD simulation analysis was also employed to check the temperature influence
on protein structure, conformation, and stability. Hence, the mutant form was
simulated twice for 200 ns at two temperature values 300 K (27°C) and 310 K (37°C).
As shown in Figure 22, the p.D151Y β-Gal form at both temperatures showed similar
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protein backbone’s RMSD values, which was fluctuating around 1.5 Å. However, after
that, the mutant at 37°C shows steep and steady rise in the RMSD values (up to 3.0 Å)
which indicates for greater change in protein conformation, whilst it remains within
the original RSMD range (1.5-1.7 Å) when simulated at 27°C. Therefore, the mutant
form of β-Gal showed more stability at lower temperature and hence it is predicted to
retain more activity compared to what it does at body temperature, which is correlated
well with the previous experimental findings.

Figure 22: Effect of reduced temperature on p.D151Y β-Gal conformation
a) Two aligned structures of the β-Gal mutant obtained from 200 ns MD simulations carried out at
27°C/300 K (red) and 27°C/310 K (cyan) b) The blot graph shows the average RMSD values of β-Gal
backbone atoms at the specified conditions over the course of MD simulation.
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3.2.11 In vitro characterization of NN- and NB-DGJ compounds for their
chaperoning effects towards β-Gal enzyme
As per the primary analysis performed using chemical chaperones and
culturing cells under low temperature, the mutated enzyme in the GM1 patient cells
has the capacity for rescue and it is a potential candidate for EET via pharmaceutical
chaperones. Building on that, the chaperoning characterizations of two well studied
DGJ derivatives PC compounds were analyzed. The IC50s of NB-DGJ and NN-DGJ
were calculated after blotting an inhibition curves for both compounds to check their
inhibitory effects on β-Gal enzyme under neutral pH (Figure 23a and 23b). Although
both NB-DGJ and NN-DGJ demonstrated significant inhibitory effect on wild type βGal activity, NN-DGJ had a lower IC50 of ~12.9 µM compared to ~225.7 µM for NBDGJ. The lower NN-DGJ IC50 is an indication of its higher affinity towards β-Gal
enzyme where it needs ~17-fold lower concentration to abolish 50% of the enzymatic
activity compared to NB-DGJ.
Heat stabilization assay is a well-known approach to indirectly assess the
effectiveness of a PC compound capacity to stabilize its target misfolded protein in the
ER were the heat in this assay imitates the missense variant effect on the enzyme
folding and stability. NB-DGJ and NN-DGJ at concentrations around their IC50s were
incubated with 10 µg of total protein lysates of normal fibroblast cells at 45°C in a
neutral buffer for various time points (Figures 23c and 23d). Concentrations lower than
the compounds IC50s showed more significant protection effect against thermal
denaturation and better maintained the enzyme activity. At all concentrations of both
compounds, β-Gal enzymatic activity was almost maintained over the time tested
compared to T= 0 for each concentration. After 20 min of incubation, the protection
effects of the lower concentrations of both compounds were more significant bearing
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in mind the compound inhibitory effect at T= 0. Again, NN-DGJ showed quite similar
protection against heat inactivation to NB-DGJ but at much lower concentrations. NBDGJ was able to protect the enzyme and maintain up to ~50% of residual enzymatic
activity after 20 min onwards compared to untreated samples (Figure 23c). NN-DGJ
on the other hand elevated β-Gal activity up to ~35% compared to untreated samples
at only with 2 µM concentration (Figure 23d).
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Figure 23: In vitro characterization of two DGJ derivatives as competitive inhibitor
chaperones of β-Gal enzyme
IC50 curves of a) NB-DGJ and b) NN-DGJ of β-Gal enzyme. Both PC compounds were incubated
with 10µg total protein lysates extracted from normal control fibroblast cells in a neutral pH buffer at
the indicated concentrations for 15 min. Then, the enzyme assay was performed at pH 3.5. The
enzymatic activities are shown as percentage of the untreated sample value. Presented activities are
averages of three individual experiments. Effects of c) NB-DGJ and d) NN-DGJ on the wild-type βGal stability at pH 7. Normal control total protein lysates were incubated in 0.1 m sodium citrate, pH
7.0, with or without the two PC compounds at 45°C for the indicated times. Then, the enzyme assay
was performed at pH 4.5. The residual enzyme activity is expressed as a percentage of the untreated
sample value at 0 time. Error bars represent ± S.E.M. of three individual experiments. (*) p < 0.05,
(**) p < 0.005, (***) p < 0.0005, and (****) p < 0.0001; two-way ANOVA followed by Tukey’s postanalysis.
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Figure 23: In vitro characterization of two DGJ derivatives as competitive inhibitor
chaperones of β-Gal enzyme (Continued)
IC50 curves of a) NB-DGJ and b) NN-DGJ of β-Gal enzyme. Both PC compounds were incubated
with 10µg total protein lysates extracted from normal control fibroblast cells in a neutral pH buffer at
the indicated concentrations for 15 min. Then, the enzyme assay was performed at pH 3.5. The
enzymatic activities are shown as percentage of the untreated sample value. Presented activities are
averages of three individual experiments. Effects of c) NB-DGJ and d) NN-DGJ on the wild-type βGal stability at pH 7. Normal control total protein lysates were incubated in 0.1 m sodium citrate, pH
7.0, with or without the two PC compounds at 45°C for the indicated times. Then, the enzyme assay
was performed at pH 4.5. The residual enzyme activity is expressed as a percentage of the untreated
sample value at 0 time. Error bars represent ± S.E.M. of three individual experiments. (*) p < 0.05,
(**) p < 0.005, (***) p < 0.0005, and (****) p < 0.0001; two-way ANOVA followed by Tukey’s postanalysis.
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3.2.12 NN-DGJ did not show any successful enzymatic enhancement in patient’s
fibroblast cells despite its higher affinity towards β-Gal
Based on the previously performed the in vitro analysis, the PC compound NNDGJ showed positively prominent chaperoning properties towards β-Gal enzyme at
very low concentrations compared to NB-DGJ. To further check the potentiality of the
PC compound to rescue p.D151Y β-Gal and promote its correct trafficking to
lysosomes, patient fibroblast cells were treated with increasing concentrations of NNDGJ (0-40 µM) for 24 hrs. Residual enzymatic activity remained almost unchanged
under NN-DGJ treatment up to 10 µM and even slightly decreased with higher
concentrations (Figure 24). Patient cells were exposed to prolonged treatment of 2 and
3 days under the same concentrations of the compound (Figure 24). p.D151Y mutated
β-Gal residual activity was significantly increased only at 2 and 5 µM of NN-DGJ after
3 days with ~1.3 and 1.4 folds, respectively. Translating the slight increase in
enzymatic activity to percentage of normal β-Gal activity, the obtained change was not
clinically significant (clinical significance in the treatment of LSDs is set to 10-15%
of normal activity) which remained under 1%.
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Figure 24: Ex vivo effect of NN-DGJ on p.D151Y β-Gal residual activity
Bar graph showing the dose response of treated GM1 patient fibroblast cells to NN-DGJ over a 3 days
period of treatment. Cells were incubated with increasing concentrations of NN-DGJ for the indicated
times as shown in each graph. Then, residual activity was measured and presented as folds increase of
untreated sample in each time point. Error bars represent ± S.E.M. of three individual experiments.

3.2.13 NB-DGJ acts as a PC for p.D151Y β-Gal in GM1 patient cells and
promoted the enzyme maturation and enhanced its residual enzymatic
activity
Alternatively, NB-DGJ was tested for its chaperoning effect at the cellular level
despite its high IC50. Patient fibroblast cells were treated to increasing concentrations
of NB-DGJ (0-1000 µM). At the enzyme maturation level, it is notable from the SDSPAGE analysis obtained that the mature form of p.D151Y β-Gal expression is higher
with ≥ 40 µM of NB-DGJ (Figure 25a). However, quantitative analysis of the SDSPAGE blot revealed that the observed increase is not significant. Despite the detected
insignificant increase of maturation at the quantitative level after one day of treatment,
NB-DGJ showed more potent effects on β-Gal activity under the same conditions. One
day post-treatment, NB-DGJ was able to enhance p.D151Y β-Gal activity in a
concentration dependent manner starting at 10 µM concentration (Figure 25b and 25c).
At 200 µM of NB-DGJ, the p.D151Y β-Gal enzymatic activity was significantly
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enhanced up to 2.5 folds that that is equivalent to ~4.5% of wild type β-Gal activity
(Figure 25b and 25c). The obtained enzymatic enhancement was slightly decreased
with higher NB-DGJ concentrations (≥ 400 µM) which can be due to the compound
inhibitory effect that increases at concentrations beyond its IC50 (Figure 25b).

Figure 25: NB-DGJ effect on p.D151Y β-Gal in GM1 patient fibroblast cells
Fibroblast cells were treated with NB-DGJ in ascending concentrations up to 1000 µg and harvested
after 1 day of treatment. a) SDS-PAGE analyses of p.D151Y β-Gal in treated cells were performed
using 15 µg total lysates. In parallel β-Gal activity were analyzed for all mentioned doses using 10 µg
of total cellular lysates and values were presented as b) percentage of residual activity in untreated
normal fibroblast cells and c) folds increase of activity in mock treated cells. Error bars
represent ± S.E.M. of three individual experiments. (*) p < 0.05, (**) p < 0.001, and (****) p < 0.0001.
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Figure 25: NB-DGJ effect on p.D151Y β-Gal in GM1 patient fibroblast cells
(continued)
Fibroblast cells were treated with NB-DGJ in ascending concentrations up to 1000 µg and harvested
after 1 day of treatment. a) SDS-PAGE analyses of p.D151Y β-Gal in treated cells were performed
using 15 µg total lysates. In parallel β-Gal activity were analyzed for all mentioned doses using 10 µg
of total cellular lysates and values were presented as b) percentage of residual activity in untreated
normal fibroblast cells and c) folds increase of activity in mock treated cells. Error bars
represent ± S.E.M. of three individual experiments. (*) p < 0.05, (**) p < 0.001, and (****) p < 0.0001.

3.2.14 NB-DGJ shows an additive and persistent effect upon treatment with
sequential doses
Since the PC compound is up taken by the cell via the endocytic pathway to be
delivered to the ER typically will request some time, it has been inspected whether an
extended treatment of NB-DGJ would show any additive increase effect on β-Gal
activity in patient cells. Using the higher concentrations (100-800 μM), patient cells
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were incubated with NB-DGJ for further 2, 3, and 6 days (Figures 26a and 26b). As
predicted, prolong treatment of NB-DGJ PC compound showed a significant time
dependent synergistic effect on the mutated enzyme activity reaching up to ~10%
activity of that in normal control fibroblast cells that is equivalent to ~6 folds increase
of untreated cells after 6 days of treatment. Interestingly, the further increase in activity
of the prolonged treatment was not influenced by the compound concentration (≥ 200
µM) which remained almost the same within each time point regardless of the amount
of NB-DGJ given to cells.
To confirm that the enhancement in p.D151Y β-Gal enzymatic activity was
due to the increase in promoting the enzyme processing into its active mature form,
lysates of 2, 3 and 6 days NB-DGJ treated and untreated patient cells were analyzed
via SDS-PAGE assay (Figure 26c). From the presented blots in Figure 26c, it is notable
that there was an increase in the expression levels of the mature p.D151Y β-Gal in a
time dependent matter that was highly significant after 6 days of the treatment which
highly correlates with the data obtained from the activity analyses in Figures 26a and
26b.
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Figure 26: NB-DGJ has a prolonged enhancement effect on enzymatic processing
and activity
Patient’s fibroblast cells have been treated with the higher concentrations of NB-DGJ for 2, 3, and 6
days and harvested for β-Gal enzymatic activity expressed as a) percentage of residual activity in
normal control fibroblast cells and b) folds increase of the activity detected in mock treated cells. c) In
parallel, SDS-PAGE analysis using 15 μg cellular lysates was performed to check the enzymatic
processing and maturation. Blots were co-blotted with actin as a loading control. Error bars in all
experiments represent ± S.E.M. of three individual experiments. (*, #, and $) p < 0.05 and (**, ##, and
$$) p < 0.001.
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3.2.15 NB-DGJ showed persistent enhancement effect on p.D151Y β-Gal in
patient’s fibroblast after washing out the compound
To check the long-term effect of NB-DGJ chaperoning effect on p.D151Y βGal, patient cells were treated with 200 and 800 µM of the compound for 3 days. Then,
the media was replaced with fresh NB-DGJ free media for another 3 days and
enzymatic activity was measured every day. At 200 µM, β-Gal activity in GM1
fibroblast cells remained constant the first two days and increased 1-fold on the third
day (Figure 27). On the other hand, it significantly increased a fold each day at 800
µM after washing out NB-DGJ from the media (Figure 27).

Figure 27: NB-DGJ continuous enhancement effects after washing it out
Patient cells were treated with 200 and 800 μM for three days and then media was replaced with fresh
NB-DGJ free media for another three days. Β-Gal enzymatic activity was measured in each single day
and the readings were blotted as folds of enzymatic activity at day 0 of the washout. Error bars in all
experiments represent ± S.E.M. of three individual experiments. (*, #, and $) p < 0.05.
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3.2.16 NB-DGJ chaperone did not show an off-target effect towards αgalactosidase enzyme in patient treated cells
The most common limitation of EET in the administration of PC compounds
is its nonspecific inhibitory effect on other structurally related lysosomal enzymes. As
previously mentioned in the introduction, DGJ PC compounds have been firstly
implemented in the therapy of Fabry disease and enhancement of misfolded α-Gal
enzymatic function carrying amenable mutations. To eliminate the chance of the
nonspecific inhibitory effect of NB-DGJ towards α-galactosidase enzyme in patient
treated cells, the cells were similarly treated with the previously tested concentrations
of the compound for three days. First, α-Gal fluorescence-based assay was optimized
using 4-MU tagged substrate. Normal control fibroblast cells were harvested in mild
0.1% triton X-100 lysis buffer and cells were sonicated for 5 seconds at low plus
power. Multiple protein lysate amounts ranging from 0-30 µg have been incubated
with 2 mmol/l 4-Methylumbelliferyl α-D-galactopyranoside substrate at 37°C for 2
hrs. The reaction was stopped with 200 µl 0.2M NaOH (pH 13). Readings were within
the linear range from 10 to 30 µg protein lysates (Figure 28a). Based on the previous
analysis, 20 μg protein lysates were incubated with 2 mmol/l α-Gal substrate at 37°C
for different time points up to 4 hrs. Florescence signals were within the linear range
from 1 to 4 hrs (Figure 28b). Finally, different enzyme substrate amounts (0-3 mmol/l)
were incubated with 20 µg protein lysate for 3 hrs at 37°C. Enzymatic activity was
stable from 2 to 3 mmol/l of substrate (Figure 28c). Overall, for the following α-Gal
enzymatic activity assays 20 µg lysates were incubated with 2 mmol/l substrate for 3
hrs at 37°C. The reaction was stopped with 200 µl 0.2M NaOH stop buffer and
florescence was read at 360 nm excitation and 445 nm emission and corrected with the
blank reading. Following the optimized protocol, α-Gal activity was measured in NB-
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DGJ treated GM1 patient cells at two effective dosses (low: 200 and high: 800 µM)
which remained within the same levels as in the untreated samples for three days
(Figure 28d).

Figure 28: NB-DGJ has no significant off target effect towards α-galactosidase
enzyme in patient treated cells
a) Lysate amount optimization blot. Protein lysates (0-30 µg) extracted from control fibroblast cells
were incubated with 2 mmol/l 4-MU tagged substrate for 2 hrs. b) Incubation time optimization blot.
20 µg lysates were incubated with 2 mmol/l 4-MU tagged substrate and florescence were measured at
different time points (0-4 hrs) c) 4-MU tagged α-Gal substrate optimization blot. 20 µg lysates were
incubated with different substrate amounts (0-3 mmol/l) and florescence readings were taken after 3
hrs incubation at 37oC. d) α-Gal enzymatic activity in NB-DGJ treated GM1 patient cells for three
days presented as percentage of residual activity in untreated normal fibroblast cells. All analyses
have been performed in duplicate, repeated three times, and standard errors were calculated.
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Chapter 4: A Novel Homozygous Missense Variant in the NAGA Gene
With Extreme Intrafamilial Phenotypic Heterogeneity
4.1 Schindler Disease: Inheritance and Mechanisms
Schindler disease (MIM # 609241) is a rare autosomal recessive lysosomal
storage disease characterized by defective alpha-N-acetylgalactosaminidase (αNAGA, EC3.2.1.49) [201]. Loss of α-NAGA enzymatic activity leads to the
accumulation of glycolipids and glycopeptides in several tissues and urine resulting
mainly in neurological problems like seizures, sensorineural hearing loss, loss of
sensation, and behavioral problems. Other symptoms may include developmental
delay, cardiomyopathy, and hepatomegaly. Schindler disease is highly heterogeneous
disorder that is divided into three subtypes (types I–III); type I disease is an infantile
neuroaxonal dystrophy associated with α-NAGA deficiency with an early onset severe
phenotype, type II disease, also called Kanzaki disease, is presented with
angiokeratoma corporis diffusum associated with α-NAGA deficiency but without
overt neurological manifestations like mild cognitive impairment with an adult-onset,
and finally type III disease is an intermediate phenotype [202-204]. To date, there is
no treatment for these disorders.
α-NAGA is encoded by the NAGA gene which is located on 22q13 comprising
9 exons. The NAGA and GLA (encoding for the α-galactosidase lysosomal enzyme)
genes are derived from a common ancestor [205]. These two enzymes share around
46% amino acid sequence identity and they are glycoside hydrolases that belong to
family 27 and clan D but with different substrate specificities. α-NAGA catalyzes the
removal of the terminal N-acetyl galactosamine (α-GalNAc) monosaccharides from
glycolipids and glycoproteins [206].
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Although α-NAGA catalyzes the removal of the terminal α-GalNAc, patients
with Schindler diseases show the accumulation of sialic acid- and galactose-terminal
saccharides as seen in sialidosis and galactosialidosis disorders. It has been suggested
that the α-NAGA glycoprotein is part of a larger macromolecular assembly (with αneuraminidase, β-galactosidase, and protective protein), and that loss of functional αNAGA leads to malfunction of the complex in the lysosome. A second possibility is
that in the absence of functional α-NAGA in the lysosome, other glycosidases such as
α-neuraminidase might work in a reverse reaction, acting as glycosyltransferases in
the presence of large amounts of enzymatic product.
To date, twelve cases worldwide with Schindler disease have been reported
that are presented by six missense mutations and one nonsense mutation. Cases were
from Germany, Japan, Netherlands, Spain, mixed French/Italian/Albanian, and
Morocco. The first Emirati case with Schindler disease will be reported in this study.
Several studies have highlighted the effects of these mutations via protein modeling
analysis and the molecular effects of these mutations have not been well studied at the
cellular level yet.
Because the population of patients with Schindler/Kanzaki disease is extremely
small, it is unlikely to be an active target for clinical development by the
pharmaceutical industry, and the neurological manifestations of the disease make
enzyme replacement therapy unsuitable. Based on the high homology between αNAGA and α-Gal, DGJ chaperone and its derivative DGJNAc have been proposed as
a possible treatment for Schindler disease. DGJNAc and DGJ increased cellular
expression of α-NAGAL by 20-30% in HEK 293T cells and can restore wild-type
cellular distribution of multiple mutants [161].
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In this thesis, the first Emirati case with Schindler disease type I with a
homozygous missense variant in the NAGA gene has been reported. The patient
presented with congenital microcephaly and severe neurological manifestations.
Whole-genome sequencing (WGS) revealed a homozygous missense variant in the
NAGA gene that was reported in the Exome Aggregation Consortium (ExAC) and
1000 Genome databases (rs578127376) in a healthy South Asian individual in a
homozygous state. Segregation analysis of the variant revealed the same variant in the
proband’s asymptomatic sister and cousin. However, enzymatic studies and molecular
diagnosis of the proband and his sister confirmed the pathogenicity of the underlying
variant further highlighting the need for more studies to understand the genotypephenotype correlation in this disorder.
4.2 Results
4.2.1 Clinical presentation
Case 1 (the proband): The proband is a 5-year-old male with congenital
microcephaly, failure to thrive, global developmental delay, dysmorphic features,
microphthalmia, bilateral dense congenital cataracts and glaucoma (Figures 29a and
29b). In the antenatal period, intrauterine growth retardation and increased nuchal
thickness were documented while the antenatal karyotype was normal. At birth, the
child was noted to have microcephaly, narrow forehead, microphthalmia, thick slightly
depressed nasal bridge, and relatively big ears. The proband also presented with
bilateral dense congenital cataracts, in which surgery was performed at 6 weeks of age.
During the neonatal period, he had anemia and thrombocytopenia, which required a
blood transfusion. During the first year, he had two episodes of metabolic acidosis,
post-cataract surgery, post-foot cast application, and required admission to the
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intensive care unit. The admission was associated with respiratory distress,
tachycardia, poor perfusion, cold peripheries, difficult IV access, high lactate (12-16)
with low pH (7.05-7.3), normal glucose, and no urine ketones during the episodes.
Since then, he did not have any further episodes of metabolic acidosis, nor history of
rapid breathing or vomiting. At 3-months old, he was noted to have an overlapping
suture and he had work-up for craniosynostosis. Regarding the developmental
milestone, he smiled and attained full head control at 8 months. He is currently rolling
over from prone and supine position, crawls on his back, and stands with support. He
reaches for objects and transfers them. He holds his hands together and can hold a cup
and drink from it. He has an only palmar grasp. Regarding his speech, he screams with
no babbling. He smiles, laughs and produces sounds. The parents described him as
friendly and easy going with everyone. No history of developmental regression. He
has poor weight gain but no feeding difficulties. He also has glaucoma, which is
managed with medication. On physical examination, his weight and head
circumference were below the third percentile (equivalent for the 50th percentile for a
newborn). He had several dysmorphic features including a triangular face, thin lips,
smooth philtrum, short frenula, and relatively large ears. His dental hygiene was poor.
There was bilateral horizontal nystagmus, left eye esotropia and absent lens bilaterally.
He had cutis marmorata of the skin and one hyperpigmented patch on his left arm.
Neurological examination revealed an increased tone of all limbs with hyperreflexia
and clonus. The patient had extensive workup including muscle and skin biopsies,
cerebrospinal fluid (CSF) analysis, craniosysnostosis, genetic workup, ammonia,
VLCFA, urine organic acid, and CDG screen all were normal. ECHO and abdominal
ultrasound were normal. Urine oligosaccharide showed an abnormal pattern consistent
with Schindler disease. Computed tomography of the brain demonstrated a complete
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fusion of the anterior third of the sagittal suture and bilateral coronal suture fusion
more on the left side. Magnetic resonance imaging (MRI) of the brain at the age of
five years old demonstrated microcephaly associated with moderate to severe
simplified gyral pattern and prominent extra-axial CSF spaces in the frontotemporal
regions. In addition, dilated perivascular spaces were also noted mainly in the left
temporal and parietal lobes along with underdeveloped Sylvain fissures bilaterally.
Assessment of the midline structure depicted a well-formed but short corpus callosum,
small pons and hypoplastic inferior cerebellar vermis (Figures 29d, 29e, and 29f).
Case 2 (proband’s sister): Identified by screening the family members for the
detected variant (Figure 30a). She is 7-year-old with conductive hearing loss as a result
of recurrent ear infections (Figure 29c). The parents reported snoring, which was
improved by post-adenoid-tonsillectomy. The urinary oligosaccharide showed the
same pattern as the affected brother.
Case 3 (proband’s cousin): Identified through premarital screening. She is a
28-year-old with a normal physical examination.
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Figure 29: Proband and his asymptomatic sister clinical features

a) full body b) and facial photographs of the proband showing microcephaly, narrow forehead,
microphthalmia, thick slightly depressed nasal bridge and relatively big ears c) the proband’s
asymptomatic sister. The brain MRI data of the proband in the lower panel showing d) Sagittal T1weighted image that demonstrates microcephaly, short well-formed corpus callosum (yellow Arrow),
small pons (red circle) and hypoplastic cerebellar vermis (white arrow) e) Axial FLAIR image
demonstrates a severely simplified gyral pattern for which there are few and shallow sulci f) Axial T2weighted image demonstrates prominent perivascular spaces in the left temporal lobe and extra-axial
CSF spaces (white patches).
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Figure 30: Family pedigree and variant analysis
a) Family pedigree of four generations. Circles and squares denote females and males respectively,
filled symbol represent the affected proband, double lines denote consanguineous marriage. * are
family individuals who were screened for the detected variants by Sanger Sequencing. ** is the
proband’s cousin who was identified through premarital screening b) DNA chromatograms of the
detected NAGA variant (homozygous and heterozygous state) compared to the wild-type sequence.
Red * represents the wild type and mutated nucleotide at position 838 of the DNA sequence c) αNAGA enzyme nucleotide and protein sequences representative of the wild type sequence around the
c.838C>A (p.L280I) detected variant (upper panel) compared to the mutated form (lower panel).
Nucleotide and amino acid changes are highlighted in yellow.

4.2.2 Whole genome analysis revealed a homozygous missense variant in exon 7
of the proband’s NAGA gene
A homozygous missense variant of unknown clinical significance in the NAGA
gene was reported via whole genome data analysis of the proband, that was segregated
in the family as confirmed by Sanger Sequencing. The proband’s parents were
heterozygous for the variant and did not show any detectable clinical symptoms. The
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reported genetic variant was found in exon 7 of the NAGA gene at position 838
(c.838C>A). Several family members were recruited and screened for the reported
missense variant via direct Sanger Sequencing as shown in the family pedigree (Figure
30a). Both the proband’s sister and the parents first cousin were homozygous for the
same genetic variant but with no significant clinical manifestations observed (Figure
30b). Some of the proband’s direct uncles and aunts were heterozygous for the
missense variant. At the protein level, it is predicted that the underlying variant will
result in an amino acid substitution change at position 280 replacing the wild type
leucine to isoleucine (Figure 30c). The missense change is not reported in the Human
Gene Mutation Database (HGMD®) but it is a known SNP (rs578127376) that has a
minor allele frequency of A= 0.0016/8 in the 1000 Genomes Project database and
0.0007497 in the ExAC database [87, 207]. Another missense variant (c.672A>C) of
uncertain clinical significance in the HMGCL gene (results in HMG-CoA lyase
deficiency) was reported by whole genome analysis. However, this variant has been
clinically excluded as the patient had normal urine organic acid, plasma acylcarnitine,
and total and free carnitine. Other reported variants from the whole genome data were
ruled out for their insignificance. The NAGA variant was analyzed by different online
mutation prediction tools to evaluate its pathogenicity. The c.838C>A variant was
predicted to be deleterious with mutation taster, SIFT, and PolyPhen2 with scores
listed in table 2. Prediction via PROVEAN, on the other hand, projected a neutral effect
of the amino acid substitution on protein function, which can be clarified by the amino
acid similarity as both leucine and isoleucine are aliphatic and hydrophobic amino
acids. At the protein level, p.L280 is highly conserved among multiple selected
eukaryotic species except for Xenopus tropicalis, as demonstrated via conservational
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analysis using multiple sequence alignments of the α-NAGA protein, which indicates
the importance of leucine at this position (Figures 31a and 31b).
Table 2: In silico prediction of the NAGA variant
In silico tools

Score

Score reference

SIFT

0.003

Neutral >0.05> Damaging

PolyPhen2

0.996

0 - Benign
0.15 - Possibly damaging
1- Damaging

PROVEAN

-1.74

Neutral >-2.5> Damaging
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Figure 31: Conservational analysis of L280 in α-NAGA
a) Schematic representation of amino acid sequence alignment around p.L280I variant in different
orthologues. The conservational analysis was performed via multiple sequence alignment b) and a
conservational logo was generated using the WebLogo online tool.

4.2.3 Despite its normal trafficking to lysosomes, p.L280I α-NAGA activities were
significantly decreased in the proband and his sister
For enzymatic analysis, α-NAGA activity was optimized via an inhouse
florescence-based assay using a 4-MU (4-Methylumbelliferyl 2-Acetamido-2-deoxyα-D-galactopyranoside) tagged substrate. First, 10 µg lysates of normal control
fibroblast cells were incubated with 1 mmol/ l substrate in assay buffer (50 mmol/ l
sodium citrate, pH: 3.5) at 37°C at different time points to optimize the incubation time
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(0-3 hrs). Florescence intensity was within the linear range over the 3 hrs time intervals
(Figure 32a). Then, a range of cell lysate amounts up to 20 µg have been incubated
with 1mmol/l substrate for 2 hrs at 37°C to optimize the best amount of protein to be
used throughout the study in measuring α-NAGA activity. The 10 µg of lysate was in
the middle of the linear range, so it was used for α-NAGA analysis for the rest of the
study (Figure 32b). To optimize the substrate amount, a range of 0-5 mmol/l of
substrate amounts were incubated with 10 µg lysate for 2 hrs at 37°C. Florescence
intensity reached a plateau at 2.5 mmol/l of substrate (Figure 32c). Overall, for the rest
of the analyses 10 µg of cell lysate was incubated with 2.5 mmol/l substrate at 37°C
for 2 hrs. Florescence intensity was subjected to a 4-MU standard curve to calculate
the amount of product released and activity was presented as nmol/ hr/ mg.
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Figure 32: α-NAGA activity optimization
a) Incubation time optimization blot for NAGA activity. Florescence intensity readings of α-NAGA
activity at different time points (0-3 hrs) using 10 µg lysates of normal control lysates b) Lysate
amount optimization blot for NAGA activity. Florescence intensity readings of α-NAGA activity
using different protein lysate amounts (0-20 µg) extracted from control fibroblast cells after 2 hrs
incubation with 1 mmol/l 4-MU tagged substrate c) 4-Methylumbelliferyl 2-Acetamido-2-deoxy-α-Dgalactopyranoside substrate optimization blot for α-NAGA activity. Florescence intensity readings of
α-NAGA activity using 10 µg lysates with different substrate amounts (0-5 mmol/ l) after 2 hrs
incubation at 37°C. Error bars are representation of three independent repeats.
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Figure 32: α-NAGA activity optimization (Continued)
a) Incubation time optimization blot for NAGA activity. Florescence intensity readings of α-NAGA
activity at different time points (0-3 hrs) using 10 µg lysates of normal control lysates b) Lysate
amount optimization blot for NAGA activity. Florescence intensity readings of α-NAGA activity
using different protein lysate amounts (0-20 µg) extracted from control fibroblast cells after 2 hrs
incubation with 1 mmol/l 4-MU tagged substrate c) 4-Methylumbelliferyl 2-Acetamido-2-deoxy-α-Dgalactopyranoside substrate optimization blot for α-NAGA activity. Florescence intensity readings of
α-NAGA activity using 10 µg lysates with different substrate amounts (0-5 mmol/ l) after 2 hrs
incubation at 37°C. Error bars are representation of three independent repeats.

The α-NAGA activity was measured in isolated leukocyte cells (extracted from
buffy coats) of all family members (affected child, his parents, and the asymptomatic
sister) and the proband’s fibroblast cells using the 4-MU tagged substrate of the
enzyme (4-methylumbelliferyl β-D-galactopyranoside). Activities are presented as
nmol/h/mg protein and the percentage of the mean activity of normal control cells
(n=4) (Table 3). The α-NAGA activity was markedly reduced in the proband’s
leukocyte and fibroblast cells with 5.9% (2.0 nmol/h/mg) and 6.8% (4.2 nmol/h/mg)
of the mean normal activity, respectively. Although the proband’s sister did not show
any significant clinical manifestations, her α-NAGA activity in leukocyte cells was
equally reduced with up to 12.1% (4.1 nmol/h/mg) of the mean normal activity.
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Enzymatic activities in both parents were approximately 40–45% of mean control
activity, that correlates well to the heterozygosity detected via Sanger Sequencing.
Table 3: α-NAGA activity analysis in proband and family members
α-NAGA activity
Leukocyte cells
nmol/ h/ mg
% of
29.8 - 39.8
Control
Activity*
34.1

Fibroblast cells
nmol/ h/ mg
% of
38 - 120
Control
Activity*
62

Control
(Range; n=4)
Control
(Mean)
Father
13.6
39.7
Mother
15.1
44.2
Proband
2.0
5.9
4.2
6.8
Asymptomatic
4.1
12.1
sister
*Calculated residual activities in samples are presented as percentage of the control
mean activity (n=4). The measured activities are a representation of three independent
experimental repeats.

To further speculate as to the reason behind the loss of function effect of the
missense variant, p.L280I α-NAGA enzymatic processing and trafficking were
analyzed. The wild type enzyme is normally synthesized in the ER and transported to
lysosomes as a 43 KDa mature form. Like the wild type, p.L280I α-NAGA is normally
transported and processed to its mature form as confirmed via the IF staining analysis
in control and patient fibroblast cells (Figure 33). p.L280I α-NAGA (green) displayed
a punctate life staining pattern predominantly colocalizing with the lysosomal marker
LAMP1 (red) as observed in the normal control cells as well. In conclusion, the
underlying variant does not interfere with α-NAGA trafficking to lysosomes.
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Figure 33: p.L280I α-NAGA is normally processed and trafficked to lysosomes
Fibroblast cells were fixed for the analysis and co-stained with anti-NAGA (green) and the lysosomal
marker anti-LAMP1 (red) antibodies. Images were captured by the Nikon Eclipse confocal
microscopy under 100× magnification. Merged images were composed and zoomed in (3×) using the
ImageJ software.

4.2.4 The p.L280I variant affects the enzyme’s natural dynamics and may
obstruct its substrate’s ability to bind to the enzyme active site pocket
The amino acid change at position 280 was generated using the specialized
computational tool, mutating leucine to isoleucine. Assessing the stability of the
mutant form, it seems there is no significant deviation compared to the wild type with
Δ Stability 0.429 kcal/mol (Table 4). Hence, the loss of α-NAGA function observed in
the phenotype is probably not because of denaturation or stability problems. These
findings shifted our attention to study the conformational details of the mutant form
compared to wild type using molecular dynamics (MD) simulations.
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Table 4: Results of computational stability assessment conducted on the
NAGA L280I mutated form

PDB

Stability

 Stability

(kcal/mol)

(kcal/mol)

Mutation

3H53

L280L

-1253.271

0.000

3H53

L280I

-1253.842

0.429

Both protein forms were simulated for 100 ns and the most representative
conformations were identified. Figure 34 shows the mutant and wild-type structures
obtained from MD simulations superimposed on each other and showing the
conformational changes resulting from this mutation. The RMSD distance for the
whole protein’s backbone amide was calculated and showed a shift of 1.7 Å, whereas
the side chains exhibited a larger shift on average (2.6 Å) as compared to the wild type
(Table 5). This means that a minor change on the whole protein was detected, however,
looking at the active site configuration, more significant changes were observed as
RMSD value raised to 2.15 Å and 3.1 Å for the main chain and side chain, respectively.
The largest shift was observed for the Asp217 side chain, which was moved by an
RMSD value of 6.64 Å with most the shifted atom moved by 11.5 Å. This observed
shift shows that Asp217 is likely a key residue in α-NAGA catalysis.
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Figure 34: The effect of p.L280I substitution on protein structural confirmation
The wild-type (blue cartoon) and mutated (green cartoon) α-NAGA structures obtained from 100 ns
MD simulations. The two conformations are aligned on the mutated structure resulting from 100 ns
MD simulations. L280 and its corresponding mutant residue (Ile) along with Leu are shown in the ball
and stick form.

Table 5: The RMSD distance between the superimposed enzymes (wild-type
and mutated)
RMSD

Maximum distance*

(Å)

(Å)

1.709

6.856

2.626

11.834

2.15

6.650

3.192

11.478

6.640

11.478

Protein region

Whole protein
(backbone)
Whole protein (side
chains)
Active site (backbone)
Active site (side
chains)
Asp217 (side chain)

*Maximum distance between the atoms of the most different atom pair.

111
Interestingly, these changes observed in the active site had a major impact on
the overall size of the catalytic pocket, which was found to be too tight to bind the
natural substrate (Figure 31d). Hence, the p.L280I seems to restrain the natural
dynamics of the protein and hinders the substrate binding and catalysis, which clearly
justifies the loss of function associated with this change.
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Chapter 5: Discussion
5.1 Brief Summary
As previously mentioned, the characteristic of LSDs is the substrate
accumulation and swelling in the lysosomes of patients’ affected tissues which is main
underlying source of the major clinical manifestations [57]. Substrate accumulation
may occur due to several cellular malformities. Primarily, most LSDs are associated
with genetic defects in highly critical genes encoding for lysosomal hydrolases,
integral lysosomal membrane proteins, transporter proteins, activator proteins, or
lysosomal function associated proteins [208]. The loss of function effects of any of
these proteins will trigger the activation of a series of cellular pathological cascades
that will lead to accumulation of undigested related metabolites in multiple tissues and
organs [2]. An equally important pathological mechanism to understand in LSDs
pathogenesis is the impairment of lysosomal related pathways that may contribute to
the occurrence of different LSDs [85]. That involves the autophagic, calcium storage,
and endosomal pathways as well as vesicle trafficking and fusion impairments [54].
The adverse clinical manifestations in many LSDs might be indirectly resolved by
increasing the residual enzymatic activities in the cases where the LSD is caused by
genetic defects in lysosomal enzymes encoding genes. By elevating the residual
activity of the defected enzyme, the digestion process of its subsequent accumulated
undegraded substrates will be enhanced to clean up the cellular storage in lysosomes
[7].
Like most of LSDs, GM1-gangliosidosis and Schindler diseases are mostly
associated with missense variants most of which are associated with structural defects.
GM1-gangliosidosis is linked with about 222 different genetic variants of which 151
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missense, 19 nonsense, 17 splicing site, and 42 indels [188]. Missense variants of all
genetic mutations are the most common reported to this disease, however, their
consequences are tricky to speculate and correlate with its clinical phenotype.
5.2 GM1-gangliosidosis
Constructing the human β-Gal enzyme crystal structure bound to its substrate
facilitate the better understanding of the pathological effect of different missense
variants based on its location at the protein level [209]. Amino acid substitutions at the
core of the enzyme are the most lethal affecting mostly the structural configurations of
the substrate binding sites or the interdomain interactions with the members of the
protective protein complex that directs the enzyme trafficking to lysosomes. A less
deleterious effect are those which are lies at the protein surface interacting mostly with
the surrounding environment. Such changes may have higher potential for rescue
through PC compounds that results in structural rearrangement of the mutated protein
to reach its native stable state. Like the p.D151Y β-Gal mutation mentioned in this
study, the infantile p.R201C variant is also located within the enzyme TIM barrel
domain on the protein surface that lead to the loss of its salt bridge with D198 [209].
The detected GLB1 variant (c.451G>T; p.D151Y) has been previously reported
in an Emirati patient with a similar clinical phenotype of the infantile (type I) form of
GM1-gangliosidosis [210]. In the previous study, the β-Gal enzymatic activity and
protein expression of the transiently transfected missense p.D151Y variant was
completely undetectable. In different circumstances, using p.D151Y patient fibroblast
cells in the current study, β-Gal precursor was predominantly expressed and even in
higher levels compared to the levels seen in normal control cells. The higher
expression levels can be explained by the enzyme retention and accumulation in the
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ER as the enzyme trafficking to the lysosomes is halted. The discrepancy in the
obtained results from the previous and our studies may reflect the effect of different
cellular expression systems which was used as patient fibroblast cells are better
representation of the disease molecular and cellular mechanism although fibroblast
cells would not be the best choice to delineate the disease phenotype because neuronal
cells are mainly the affected tissue in GM1-gangliosidosis. Also, the expression
construct type and/or tag may produce different expression levels as well as transient
expression may overload the transiently transfected cells with a huge amount of
proteins halting the cell normal molecular mechanisms and pathways.
Hydrophobic regions in most proteins are imbedded in the protein core away
from the surrounding solvent [211]. In wild type β-Gal, the aspartic acid at position
151 is exposed to the protein surface due to its negatively charged side chain. As a
consequence of substituting the wild type negatively charged amino acid with a
tyrosine, the hydrophobic side chain of the new amino acid will be exposed to the
surrounding solvent which is not its favorable environment that will eventually initiate
the formation intermolecular bonds with other misfolded enzymes forming aggregates
in the ER.
Pre-analysis can be performed to check the amenability of a certain mutation
and its potentiality for rescue using chemical chaperones like glycerol or through
manipulating its thermodynamic properties. Glycerol is an osmolyte that indirectly
manipulates the interactions between the misfolded enzyme and its surrounding
solvent to increase its solvation by masking the surface hydrophobic residues
preventing its aggregation [212]. Glycerol has been successfully able to resolve the
formation of aggregates in the ER of affected cells and partially restore the mutated
enzyme function as reported in many conformational diseases [199, 213]. Glycerol
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significantly promoted p.D151Y β-Gal enzyme processing and transportation to the
lysosomes where it partially retained some of its functional activity. Similarly, but in
more prominent effect, culturing patient fibroblast cells under reduced temperature
demonstrated significant improvement in p.D151Y mutated β-Gal maturation,
localization, and enzymatic activity that was accomplished through increasing the
enzyme stability by manipulating its thermodynamic properties. Incubating affected
GM1 patient cells with glycerol under reduced temperature is not feasible to be
translated to the clinical therapeutics. However, it is a strategy to provide a proof of
principle that the underlying tested mutation can be manipulated at the conformational
level increasing its opportunity to be a potential candidate for EET by PC compounds.
Up to date, palliative management is the only interference that is available to
GM1-gangliosidosis patients as there are no available medications has been approved
for this disorder. The implication of small molecular weight compounds such as
pharmacological chaperones has been extensively studied in different LSDs. The ER
quality control machinery is designed to recognize the exposed hydrophobic regions
due to amino acid substitution mutations in de novo proteins as they will be tagged as
misfolded polypeptides halting their trafficking where they will be retained in the ER
or sent for degradation [214]. Misfolded protein conformational stability can be
promoted through manipulating its thermal properties by the binding to its active site
domain [215]. Based on this concept, enzyme competitive inhibitors in LSDs therapy
are mostly active site ligands that assist misfolded retained enzymes harboring
amenable variants that holds intact active site to be rescued and promote their correct
trafficking to the lysosomes [216]. As mentioned above, NOEV is one of the most
effective PC compounds that successfully rescued about one third of the studied GM1gangliosidosis patient cell lines mostly from the juvenile and adult forms [140, 217].
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In R201C GM1 transgenic mouse model, NOEV was able to reach the mice brain
tissue and cross the blood brain barrier, increase β-Gal activity, slow the disease
progression, and elevate the mice life expectancy [218]. Despite its effective response
in various mutants (20-40% of tested mutants), NOEV is mutation specific resembling
most of the available PC compounds as there is no compound to date that can cover
the enhancement of amenable variants [217]. A similar substitution to our reported
p.D151Y, p.D151V missense variant is also associated with the infantile form of GM1gangliosidosis, but the wild type aspartic acid in this case is replaced with valine
instead of the reported tyrosine [180]. Like tyrosine, valine is a hydrophobic amino
acid that is expected to negatively interfere with the β-Gal 3D structure and
conformation. In patient fibroblast with p.D151V missense variant, NOEV treatment
did not display any positive effect towards β-Gal residual activity [219]. As a result,
more PC compounds has been synthesized and tested for better coverage of the
reported GM1 amenable variants. Multiple DGJ derivatives have exhibited a range of
positive chaperoning effect in multiple GM1 missense variants [219]. Here in, the
chaperoning effect of two DGJ derivatives were evaluated on the reported GM1
infantile p.D151Y variant using patient fibroblast cells.
Due to its extra N-alkyl group, NN-DGJ showed higher specificity and binding
affinity towards β-Gal enzyme as the compound act as an active site competitive
inhibitor of the enzyme [193]. The compound exhibited higher inhibitory effect at
neutral pH which was almost twice greater than that detected at the lysosomal acidic
environment, but at the cellular level a ~15 folds higher concentration than the NNDGJ IC50 was needed to exert its chaperoning function. The compound significantly
enhanced β-Gal function in three patients’ fibroblast cells of the juvenile and adult
forms and promoted its maturation and trafficking to lysosomes. Most of the amenable

117
variants in the mentioned study were located at the protein surface resulting in milder
rearrangement at the structural level as shown by modulation analysis [209]. Despite
its ability to ameliorate β-Gal activity in the infantile heterozygous missense variant
(p.R148S/p.D332N) up to ~2- and 3- folds increase, NN-DGJ observed enhancing
effect was not clinically significant (<10% of normal activity) [193]. The amino acid
change in p.D151Y mutated β-Gal is also located at the protein surface and showed
significant enhancement under NB-DGJ treatment but NN-DGJ failed to achieve a
significant clinical improvement even under prolong treatment.
Like NOEV, NB-DGJ showed similar positive response in enhancing β-Gal
functional activity in GM1 and transfected cellular systems but with used of ~2500
folds higher concentrations to achieve the detected outcome [218]. Under four days of
NB-DGJ treatment, misfolded β-Gal activity in juvenile and adult forms of GM1patient and mice transfected cells was significantly improved into various levels
reaching up to ~6 folds increase [220]. In the presented GM1-gangliosidosis case, the
rescue effect of NB-DGJ was highlighted at the molecular and cellular level in patient
fibroblast cell line expressing the amenable p.D151Y variant that results in an infantile
type I form of the disorder. The compound significantly increased p.D151Y β-Gal
residual enzymatic activity up to 6 folds (10% of normal control) with only 0.2 mM
concentration within 2 more days of treatment. Activity enhancement was associated
with increased enzymatic processing and trafficking to lysosomes.
The effective response to NB-DGJ chaperoning activity was maintained in
patient cells for 3 more days after washing out the compound form the cell culture
media. This can explained due to the enzyme long half-life as human α-Gal which is
homologous to β-Gal has more than 100 hrs half-life while the bacterial (Bacillus
circulans) β-Gal has around 220 hrs half-life [139, 221]. In addition to its chaperoning
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effect, NB-DGJ was found to a better substitution of its glucosyl counterpart NB-DNJ
used in SRT of multiple LSDs to inhibit GSL biosynthesis with the lowest off target
inhibitory effects detected upon NB-DNJ treatment [222]. Moreover, NB-DGJ was
capable to decrease the accumulation of gangliosides in both β-gal knockout mice
brains [223]. Therefore, NB-DGJ is a double edge therapeutic compound that can be
applied in patients carrying amenable variants as both EET and SRT. The use of EET
via PC compounds is not always the right choice in the treatment of LSDs with
missense mutations as presented in the next clinical case of Schindler disease.
5.3 Schindler Disease
Collectively, LSDs are considered to be common in the United Arab Emirates
with a prevalence of 26.9 per 100000 live births as GM1-gangliosidosis disease is the
most frequent [44]. Among the Emirati population, 16 different LSDs’ associated
mutations where reported of which 9 (56%) from the missense type [44]. Among the
oligosaccharide subgroup, fucosidosis, α-mannosidosis, and mucolipidosis II/III were
reported in Emiratis [44]. In the presented study, a patient with congenital
microcephaly, microphthalmia, cataracts and psychomotor retardation with urine
oligosaccharide pattern compatible with Schindler disease has been reported. The
patient’s brain MRI images showed microcephaly, simplified gyral pattern, prominent
extra-axial CSF spaces, dilated perivascular spaces, underdeveloped Sylvain fissures,
a short corpus callosum, a small pons, and a hypoplastic inferior cerebellar vermis.
Here in, the first radiological and MRI analyses of Schindler disease case has been
reported.
The patient’s WGS revealed the presence of a homozygous missense variant
in the NAGA gene that results in a substitution of the highly conserved leucine to
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isoleucine at position 280. The underlying amino acid substitution resulted in the loss
of α-NAGA residual enzymatic activity to less than 7% of normal control which is
considered clinically significant [224]. To further investigate at which level the amino
acid substitution led to the reported loss of functional enzymatic activity, p.L280I αNAGA processing, trafficking, stability, and conformation were analyzed. The αNAGA enzyme is synthesized in the ER where it undergoes multiple folding steps to
reache its fully folded native state and capture a M6P residue on its high mannose that
facilitate its trafficking to lysosomes through the M6P receptor dependent pathway
[225]. Deleterious missense variants in LSDs have showed its effect at the expression
level where as other types of missense mutations may alter the protein structure and
halt its trafficking to the lysosomes keeping it trapped in the ER [7, 226].
In the Schindler case presented, p.L280I α-NAGA was normally expressed and
transported to its final destination in the lysosomes as demonstrated via IF staining of
the patient’s fibroblast cells. Another probable mechanism by which amino acid
substitution may result in the loss of enzymatic function is by manipulating its
structural stability leading to its premature degradation in the ER via the ERAD
machinery [7, 137]. The performed stability report in this study showed clearly that
the p.L280I variant did not affect the enzyme stability in contrast to its wild type form.
Multiple docking studies have highlighted that the majority of the reported missense
variants associated with Schindler disease have indirectly affected the binding affinity
of the affected α-NAGA active site pocket to its ligand due to smaller catalytic cleft as
a results of the conformational changes resulted from these variants [227]. Likewise,
p.L280I via MD simulation analysis was found to markedly manipulate the mutated
protein conformation and structure specifically at the level of the enzymatic active site
by generating a major shift to the catalytically critical Asp217 amino acid leading to a
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smaller active site space and in turn making it hard for the substrate to bind to the
enzyme.
As shown in the family pedigree, multiple closely related members of the
family were screened for the detected genotype which surprisingly identified that the
proband’s healthy sister and cousin were homozygous for the mentioned variant. At
the Clinical level, α-NAGA deficiency disease is extremely heterogeneous disease
covering a wide range of clinical phenotypes that ranges from the very severe
Schindler type I with manifestations including neuroaxonal dystrophy, psychomotor
retardation, epilepsy, hypotonia, and microcephaly to asymptomatic individuals to
asymptomatic cases (Table 6) [228].
A total of seven missense variants have been reported in the HGMD along with
mutation reported in the current study, affecting 13 individuals from 8 families (Table
6) [204]. Two patients were clinically presented with angiokeratoma corporis
diffusum: the adult form of Schindler disease (type II). Six patients had Schindler
disease (type I) who presented with psychomotor retardation, microcephaly, hypotonia
and cataracts; five individuals (38%) were healthy even though they had the same
genotype as their affected sibling as well as α-NAGA enzyme deficiency and abnormal
urine oligosaccharide pattern [178, 202, 204, 229, 230]. The two Dutch siblings
reported by Keulemans et al, (1996) had compound heterozygous variants (p.S160C/
p.E325K) in the NAGA gene resulting in severe infantile (type I) Schindler disease in
the older child (5-year-old), whereas her younger brother (one-year-old) was
asymptomatic [229]. A similar case has been reported in a Moroccan family with two
siblings carrying the most severe homozygous variant (p.E325K) that was previously
reported in the German case associated with neuroaxonal dystrophy [204, 230]. The
younger Moroccan sibling (3-year-old) presented with congenital bilateral cataracts
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and psychomotor retardation, whereas the 7-year-old brother was asymptomatic even
though both showed similar abnormal urinary oligosaccharide pattern as well as
undetectable -NAGA activity in leukocytes and a profound deficiency in fibroblasts
[204]. The extreme paradox in the genotype-phenotype correlation of the German and
Moroccan families carrying the same genotype has led to the assumption that there is
a presence of additional genetic disease in severe cases along with NAGA variants
[228]. In the current study, the proband had extensive genetic metabolic workup
including whole exome sequencing and WGS, which revealed only homozygous
NAGA variants. Nevertheless, the possibility of another genetic disease of the proband
cannot be excluded especially in the highly inbred Emirati population.
Moreover, it is well known that LSDs have significant clinical variability
among patients even within the same genotype [231]. The limitation in the genotypephenotype correlation can be a consequence of many reasons, one of which is the
influence of modifier genes [232]. Genetic modifiers are genetic variations in related
genes distinct from the disease-causing ones. Such variations may affect disease
symptoms severity, onset, and progression. Gaucher and Pompe diseases are the most
common LSDs that are associated with modifier genes [233, 234]. As in many rare
diseases, studying and identifying modifier genes in Schindler disease is challenging
due to many reasons such as the small population of affected individuals, low allelic
frequencies of the detected disease-causing variants, the extreme clinical heterogeneity
of the disease, and population heterogeneity [235].
So, due to its different consequences, the type and nature of the underlying
missense variant in LSDs should be identified in order to apply the correct therapeutic
intervention. The generation of different LSDs biomarkers to facilitate the diagnosis
process, monitor the patient’s clinical progression and enhance the chosen therapeutic
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approach is crucial objective in the study of lysosomal disorders especially for those
which are associated with neurological manifestations. More importantly is the early
diagnosis of LSDs a while before the appearance of its symptoms more critically the
CNS and bone involvement in order to implicate the right therapeutic intervention and
slow down the disease progression that heavily relies upon its early discovery. The
identification of the disease before its occurrence will eliminate dealing with the
irreversible symptoms that is associated with most of LSDs. In hematopoietic
transplantation as a chosen therapy approach, the early diagnosis of the disease at the
neonatal stage will overcome the therapy drawback of immune rejection when
grasping that chance and perform the procedure at the time when the newly born has
naturally suppressed immune system [236]. In addition to providing a better therapy
outcome, early diagnosis will save the patient from the prolonged and hectic process
of diagnosis as known in the clinical field a confirmatory diagnosis for an LSD might
take months which might exceed a year in the case of the ultra-rare diseases like
Schindler disease. Saving that time on the patient and his family to think about the
therapy and disease management would be a better choice than spending it on a
stressful process of clinical diagnostic procedures. Also, it is a great opportunity for
the family through the newborn screening to get the proper genetic counseling and
provide them with reproductive choices [42]. The development of newborn screening
programs for LSDs for the whole population as group is much cost effective than its
individual application taking in confederation its relatively high incidence (1:5000
collectively compared to phenylketonuria (1:14,000) that is routinely included in the
screening programs [237]. Many therapeutic approaches are arising and developed for
the treatment of LSDs but still there is a huge shortage in covering all types of these
disorders. Consequently, the early diagnosis of an incurable disease in a newborn
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might be an emotional hazard and difficult for the patient and his parents. Such an
issue should be taken in consideration while developing and/or implementing any
future screening plan.
The current development of newborn screening is based on the combination of
two early investigational approaches that is based on the biology of LSDs. First, the
use of certain lysosomal proteins as a diagnostic markers for the detection of LSDs
[236]. This approach is based on the idea that in LSD affected cell number and size of
lysosomes will highly increase as much as 50% of total cellular volume. That will be
accompanied with the increase of certain lysosomal protein such as the saposin
proteins and the lysosome associated membrane proteins LAMP-1 and LAMP-2 [238].
At this stage, the later approach can be used as a primary screening method where
newborns with high risk of having any LSDs will be shortlisted for the next stage of
screening that is more specific and precise. The main feature of LSDs is the
accumulation of its undegraded substrates in the lysosomes that will eventually be
secreted to the affected induvial blood or urine by exocytosis or cell death. Using a
high throughput tandem mass spectrometry protocol to quantify the stored metabolites
in dried blood spots of the newborns who were found in high risk for LSDs is the
second phase of the screening program [236]. Individuals who will be positive for both
the lysosomal markers and accumulated substrates will undergo further enzymatic
analysis to confirm the presence of the LSD and will be directed to proper counselling
and therapeutic intervention in the early stage of the disease. Newborn screening and
early detection of LSDs alone is not enough where multiple other issues should be
taken in consideration.
In addition to the development of early diagnosis and treatment methods, an
accurate approach of prognosis prediction tool should be accomplished for the
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physicians to decide on which treatment regimen the patient should follow even before
the disease onset. It can be accomplished by finding a better way to understand the
genotype/phenotype correlation in different LSDs which can be pictured by enzymatic
analysis or the amount of the accumulated substrate in the affected patient. It is also
crucial to develop a follow up analysis to evaluate the progress and the effectiveness
of the applied therapy even in patients who did not develop any symptoms at this stage
and was early diagnosed.

Table 6: Summary of all reported missense variants resulting in α-NAGA deficiency

Variant

p.S160C

HGMD
accessio
n

CM9610
15

Exon

4

Genotype

Compound
heterozygous
with E325K

Effect on protein structure

Disturbs the active site
disulfide bond at C127-C158

Residual
activity in
fibroblast
(nmol/h/mg)

3.2

Type

I

Age of
onset

Phenotype

1 year

5-year-old Female with
multiple convulsions
associated with fever led to
psychomotor retardation and
hypotonia.

Coil at 51–53 is predicted to
be converted to helix
-

-

I

8
months

Compound
p.D217
N

CM0784
22

6

heterozygous
with E325K

Directly disturbs the active
site

1.75

-

7

Homozygous

Reference

[229]
Dutch
[178]

3.6-year-old asymptomatic
boy
Hepatomegaly and
cardiomyopathy

Spanish

[239]

Emirati

Current
study

(early onset and death)

4.2

p.L280I

Ethnicity

I

At birth

Congenital microcephaly,
Cataract, Psychomotor
retardation, and dysmorphic
features

Hinders substrate binding to
the active site
4.1 (WBC)

-

-

A 7-year-old female with
conductive hearing loss and
history of snoring

-

-

-

28-year-old female healthy
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Table 6: Summary of all reported missense variants resulting in α-NAGA deficiency (Continued)

Variant

p.E325K

p.R329
Q

HGMD
accession

CM90016
9

CM01538
8

Exon

8

8

Genotype

Homozygous

Homozygous

Effect on protein structure

Loss of an ion pair between
E325 and R316

Disrupts hydrophobic core
affecting protein stability

Residual
activity in
fibroblast
(nmol/h/mg)

Typ
e

Age of
onset

Phenotype

Ethnicity

0.5

I

≤ 1 year
old

Neuroaxonal dystrophy with
severe epilepsy, psychomotor
retardation, and hypotonia

German

1.0

-

-

Asymptomatic

1.9

I

1
month

A 3-year-old female with
psychomotor retardation and
cataract

p.R329
W

CM94108
8

8

Homozygous

Compound
p.E367K

CM01034
9

8

heterozygous
with E325K

[230]
[202]

Moroccan

1.0

-

-

7 years old - healthy

In plasma:
0.77% of
control

II

20
years

Angiokeratoma corporis
diffusum and Meniere's
syndrome with hearing loss

Japanese

Adultonset

Angiokeratoma corporis
diffusum and glycopeptiduria

Japanese

3 years

intellectual impairment, and
severe autistic form behavioral
problems

French/Itali
an/Albania
n

(0.014
nmol/h/ml)
Disrupts hydrophobic core
affecting protein stability and
expression

< 1% of
control

II

Disrupts protein-protein
interactions with the
lysosomal complex (αneuraminidase, βgalactosidase, and PPA)

-

I

Reference

[204]

[228]
[178]

[203]
[178]

[204]
[178]
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Chapter 6: Conclusion
Lysosomal storage disorders are an important topic in the clinical field that
attracted considerable attention to better understand the pathophysiology of such group
of disorders and apply the knowledge obtained for the development of new therapeutic
and diagnostic approaches. However, there are still many challenges and numerous
open questions regarding LSDs that warrant further rigorous research efforts to better
establish their mechanisms and pathogenesis as well as other aspects. For instance, the
variation in the disease onset that may range from early childhood to adolescence as
well as the poor genotype/phenotype correlation in LSDs. It is not uncommon that two
individuals having the same null homozygous genetic variant have presented with
variable phenotypes that can be extreme, ranging from a severe disease phenotype to
asymptomatic carrier of the disease (the presented Schindler cases in the current study
and in the literature as examples). How critical and detrimental are the effects of
modifier genes and environmental factors to the presentations of LSDs is another
major challenge requiring extensive research efforts [240, 241]. Such topic has been
taken into consideration in multiple studies regarding Gaucher and Pompe diseases
[233, 242]. Due to the need of large number of participants to obtain a significant
conclusion and identify allele variants that may influence the disease onset and
severity, it is hard to apply these kinds of studies on rare LSDs like Schindler disease.
Alternatively, animal models with different genetic backgrounds can be used to
identify some modifiers that may elucidate the phenotypic variability in rare LSDs
[241, 243]. Another debatable question is whether the use of enzymatic activity
analysis alone would be the right sensitive way to evaluate the prognosis for LSDs or
the administrated treatment especially in patients presented with almost complete loss
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of residual enzymatic activities [244]. Alternatively, the combination of other clinical
analysis like measuring the rate and amount of accumulated substrates in different
biological samples like urine and serum in addition to enzymatic activity measurement
would give more precise evaluation of the disease prognosis and the effectiveness of
the underlying treatment. Furthermore, the use of knockout LSD mice models would
help in understanding the main basics of each disease taking the advantage of the short
life span of these animals, however, it is difficult to use the mentioned in vivo models
in studying LSDs associated with some degree of residual activities due to missense
mutations [244]. The use of knock in animal models can help in such cases but would
not be a practical solution to cover every disease-causing missense variant reported as
for example more than 115 missense variants were reported for GM1-gangliosidosis
as mentioned earlier. It would be much more feasible to look up for a more practical
solutions for that in order to cover as much of the reported LSDs point mutations. For
instance, high through put screening methodologies can be used to study a specific
therapeutic compound using different patients’ derived fibroblast cells. Building up a
GM1 patients’ derived fibroblast cells library with different genetic defects to evaluate
the detected chaperoning effect of NB-DGJ would expand our knowledge for the
studied compound. This approach has been applied to multiple chaperone compounds
like the chemical chaperone ambroxol which was tested in a group Gaucher patients’
primary cells such as fibroblasts, macrophages, and peripheral blood mononuclear
cells [245]. Another complicated side of LSDs is to predict the molecular response of
different cell type towards the underlying effects of the disease and its accumulated
substrates [57]. They might show different rates of storage accumulation, other
pathways activation, the way by which they deal with the stored substrates [244].
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The current study highlighted the main various effects of amino acid
substitutions due to missense variants at the molecular and cellular level in the
development and pathogenesis of two LSDs (GM1-gangliosidosis and Schindler
diseases as examples). Effects ranging from the ER retention of the mutated enzyme
as a result of structural malformation to a complete irreversible loss of function effect
due to destructive active site configurations. Other consequences may also occur like
complete diminish the enzyme expression or its truncation as early as its transcription.
Understanding the missense variant nature and the type of its underlying effect will
positively influence the future decision in analyzing the patient clinical status and the
corresponding therapy including the development of novel personalized therapies.
This thesis also, highlighted the additive positive influence of structural and MD
simulation analysis of mutated protein in predicting the effect of the causative genetic
defect on the structural level which will assist the understating the mutation effect on
the enzyme at the molecular level, hence, providing a clearer picture of the variant
pathophysiology. Recently, a SAAMP algorithm has been built to predict the
consequences of point mutations on protein function and structure [246]. The software
has been tested on previously known disease-causing mutations of the GLB1 gene to
try to establish a phenotype-genotype correlation for these mutations. The built
algorithm showed around 94% sensitivity and 90% specificity. It is therefore advisable
to include such analysis along with the routinely used approaches in the diagnosis and
clinical clarifications of LSDs.
In EET via PC compounds showed its ability to enhance and rescue LSD loss
of enzymatic function but it was found to be mutation specific and even the
enhancement degree varies from mutation type to another (NN-DGJ vs NB-DGJ effect
on p.D151Y β-Gal) regardless of its specificity and binding affinity to the targeted

130
enzyme. In order to pick the successful PC compound for the detected defect, high
throughput screening approaches should be developed. Of which generating chemical
libraries where a purified enzyme is applied with a set of proposed PC compounds to
check for a chaperoning effect mainly based on binding affinity. These screening
libraries have been used to identify chaperoning compounds for glucocerebrosidase
that have been further studied for possible therapeutic purpose [247, 248]. A second
screening method is the use of cell-based fluorescence method to directly evaluate the
chaperoning capability of a library of chemical via enzymatic activity. There is a great
need for the development of more strategies of screening methodologies.
Another critical limitation of the use of patient fibroblast cells in this study is
such model is not the optimum reflection of the disease phenotype because in both
GM1-gangliosidosis and Schindler disease the affected cells are the neuronal and CNS
related cells. For that reason, the PC compounds chaperoning function assessment at
the substrate level were hard to be performed where fibroblast cells did not show
substrate accumulation. This can be overcome through remodeling and
reprogramming of the patients’ cells to its neuronal lineage via iPCs but that a very
demanding task and time consuming. An MPS II specific iPSC-based in vitro model
has been programmed from patient’s PBMC [249]. The cellular model showed a very
close replication for the disease phenotype which provides a better understanding for
the underlying disease and facilitates the evaluation of any proposed therapeutic
approaches.
The obtained PC analysis of NB-DGJ is a primary data that needs to be
translated into an in vivo model in order to be develop to clinical trials. The data
detected reflects the compound effect at the cellular level which would be modified
when translated in vivo where at the systematic level there are many players that may
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influence the drug effect. The drug effects at the cellular level were obtained at an
optimized concentration where it was carried with the whole study but it should be
taken in consideration that at the systematic level the concentration should be reoptimized based on the applied model as many factors like compound absorption,
cellular uptake, drug bioavailability may influence the drug function. Luckily, the
compound has been evaluated in clinical trials as a substrate reduction compound
which facilitates its testing for chaperoning therapy [155]. Based on the reported trials,
NB-DGJ (Lucerastat) was safe and well tolerated in healthy individuals which make
it easier to translate studies like ours to the clinical trials.
Overall, therapy using PCs compounds is still in its early stages, but it
demonstrated promising outcomes in multiple LSDs as well as the combination use of
these compounds with other conventional therapies like ERT or SRT for the
enhancement clinical outcomes is also suggestable. Combination therapy could be a
suitable solution to overcome the drawbacks of singular therapies. It can be a way to
target multiple affected organs and systems at the same time (visceral organs and CNS)
[250]. Targeting both the destructive enzyme via PCT/ERT and the accumulated
substrates via SRT could be a dual therapeutic approach to obtain a better prognosis
[135, 251]. Therefore, extensive and rigorous research efforts are needed to fully
elucidate and understand the cellular mechanisms of LSDs as well as expand the
identification of more small molecules to correct some of the underlying cellular
defects as novel therapies especially for untreatable and life-threatening LSDs.
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